WO2013038381A1 - Pyridine/pyrazine amide derivatives - Google Patents

Pyridine/pyrazine amide derivatives Download PDF

Info

Publication number
WO2013038381A1
WO2013038381A1 PCT/IB2012/054820 IB2012054820W WO2013038381A1 WO 2013038381 A1 WO2013038381 A1 WO 2013038381A1 IB 2012054820 W IB2012054820 W IB 2012054820W WO 2013038381 A1 WO2013038381 A1 WO 2013038381A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
ci
selected
nr
Prior art date
Application number
PCT/IB2012/054820
Other languages
French (fr)
Inventor
Darren Mark Legrand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161535707P priority Critical
Priority to US61/535,707 priority
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2013038381A1 publication Critical patent/WO2013038381A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides

Abstract

The present invention provides pyridine/pyrazine amide derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. Formula (I):

Description

Title

Pyridine/pyrazine amide derivatives

Field of the invention

This invention relates to pyridine/pyrazine amide derivatives, their preparation and use as pharmaceuticals.

Background

Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)- activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung. Most CF mutations either reduce the number of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both. There are currently no approved therapies that target CFTR directly. The present invention discloses compounds which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced).

Description of the invention

In a first aspect, the invention provides compounds according to Formula I:

Figure imgf000002_0001
wherein:

A is N or CR ,'4a. R is selected from C-i-C8-alkyl substituted by a substituent selected from CrC4 alkoxy, - N R iaR i b _C(=0)Cl_C4 aikyl, -C(=0)OCi-C4 alkyl and -C(=0)NR aR ; C2-C8 alkenyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -

Figure imgf000003_0001
; C2-C8 alkynyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OC C4 alkyl and - C(=0)NR aR ;

R a is selected from H and Ci-C4 alkyl optionally substituted with one or more halogen atoms;

R is selected from H, -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, d-C4 alkyl optionally substituted with one or more substituents selected from halogen atoms, OH, d-C4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;

or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents;

R2 is Ci-C4 haloalkyl;

R3 is H or C-i-Ce alkyl optionally substituted by one or more halogen atoms;

R4a is selected from H; halogen; C C4 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; -(C0-C4 alkyl)-C6-Ci4 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclyl; Ci-C8 hydroxyalkyl; -(CH2)m-NR 7R18; -(C0-C4 alkyl)-C02R15 and -(C0-C4 alkyl)-C(0)NR 7R18;

R4 is H, or C C8 alkyl optional substituted with one or more halogen; R5 is -(CH2)m-NR 7R18, -(CH2)m-OR'; C C8 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C02R15; -(C0-C4 alkyl)-C6-Ci4 aryl or -3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; wherein the -(C0-C4 alkyl)-C6-Ci4 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group are each optionally substituted by one or more Z substituents;

R6 is Ci-C8 alkyl optionally substituted by one or more halogen atoms; C3-Ci0 cycloalkyi; -C1-C4 alkyl-C3-C8 cycloalkyi; C C8 alkoxy optionally substituted by one or more halogen atoms; OH; CN; halogen; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; wherein the cycloalkyi, cycloalkenyl, -(C0-C4 alkyl)-C6-C14 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group are each optionally substituted by one or more Z substituents; or

R6 is H, and R5 is -(CH2)m-NR 7R18, -(CH2)m-OR', C C8 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-C14 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; or -(C0-C4 alkyl)-C02R15, wherein -(C0-C4 alkyl)-C6-Ci4 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group groups are each optionally substituted by one or more Z substituents; or

R4 and R6 together with the carbon atoms to which they are bound form a 3 to 8 membered carbocyclic ring system; or

R4 and R5 together form an oxo group (C=0) and R6 is C C4 alkyl optionally substituted by one or more halogen atoms; C C4 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or

R5 and R6 together with the carbon atom to which they are bound a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; or R4 and R5 and R6 together with the carbon atom to which they are bound form a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents;

R is H, or CrCe alkyl optional substituted with one or more halogen; m is 0, 1 , 2 or 3; R8, R , R 3 and R 7 are each independently H, CrC8 alkyl optionally substituted by one or more halogen atoms, C3-Ci0 cycloalkyl or -(C1-C4 alkyl)-C3-C8 cycloalkyl;

R9, R 0, R 2, R 4, R 5, R 6 and R 8 are each independently H; C C8 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; C2-C8 alkynyl; C3-Ci0 cycloalkyl; C5-Ci0 cycloalkenyl; -C C4 alkyl-C3-C8 cycloalkyl; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or

R8 and R9, R and R 2, R 3 and R 4, and R 7 and R 8 together with the nitrogen atom to which they are attached may form a 4 to 14 membered heterocyclic group optionally substituted by one or more Z substituents; Z is independently OH, aryl, O-aryl, benzyl, O-benzyl, C C6 alkyl optionally substituted by one or more OH groups or NH2 groups, C C6 alkyl optionally substituted by one or more halogen atoms, C C6 alkoxy optionally substituted by one or more OH groups or C1-C4 alkoxy, NR 8(S02)R21 , (S02)NR 9R21 , (S02)R21 , NR 8C(0)R21 , C(0)NR 9R21, NR 8C(0)NR 9R21 , NR 8C(0)OR19, NR 9R21, C(0)OR19, C(0)R19, SR 9, OR19, oxo, CN, N02, halogen or a 3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; R 9 and R2 are each independently H; C C8 alkyl; C3-C8 cycloalkyl; C1-C4 alkoxy-Ci-C4 alkyl; (C0-C4 alkyl)-aryl optionally substituted by one or more groups selected from d-C6 alkyl, C C6 alkoxy and halogen; (C0-C4 alkyl)- 3- to 14-membered heterocyclic group, the heterocyclic group including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, oxo, C C6 alkyl and C(0)Ci-C6 alkyl; (C0-C4 alkyl)-0-aryl optionally substituted by one or more groups selected from Ci-C6 alkyl, Ci-C6 alkoxy and halogen; and (C0-C4 alkyl)- 0-3- to 14- membered heterocyclic group, the heterocyclic group including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, C C6 alkyl or C(0)CrC6 alkyl; wherein the alkyl groups are optionally substituted by one or more halogen atoms, CrC4 alkoxy, C(0)NH2, C(0)NHC"|-C6 alkyl or C(0)N(Ci-C6 alkyl)2; or

R 9 and R2 together with the nitrogen atom to which they attached form a 5- to 10- membered heterocyclic group, the heterocyclic group including one or more further heteroatoms selected from N, O and S, the heterocyclic group being optionally substituted by one or more substituents selected from OH; halogen; aryl; 5- to 10- membered heterocyclic group including one or more heteroatoms selected from N, O and S; S(0)2-aryl; S(0)2-Ci-C6 alkyl; Ci-C6 alkyl optionally substituted by one or more halogen atoms; C C6 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy; and C(0)OCrC6 alkyl, wherein the aryl and heterocyclic substituent groups are themselves optionally substituted by Ci-C6 alkyl, Ci-C6 haloalkyl or Ci-C6 alkoxy;

or a pharmaceutically acceptable salt thereof. Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments.

In an embodiment of the invention as described anywhere herein, R is selected from d- C4-alkyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OC C4 alkyl and -C(=0)NR aR ; C2-C4 alkenyl substituted by a substituent selected from CrC4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OC C4 alkyl and - C(=0)NR aR ; C2-C4 alkynyl substituted by a substituent selected from C1-C4 alkoxy, -

N R iaR i b .c^ojd-CA alkyi, -C(=0)OCi-C4 alkyi and -C(=0)NR aR ;

R a is selected from H and C C4 alkyi optionally substituted with one or more halogen atoms;

R is selected from H, -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, d-C4 alkyi optionally substituted with one or more substituents selected from halogen atoms, OH, d-C4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;

or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents.

In an embodiment of the invention as described anywhere herein, A is N.

In an embodiment of the invention as described anywhere herein, A is CR4a.

In an embodiment of the invention as described anywhere herein, R2 is CF3CF2-, (CF3)2CH-, CH3-CF2-, CF3CF2-, CF3, CF2H-, CH3-CCI2-, CF3CFCCIH-, CBr3, CBr2H- CF3CF2CHCF3 or CF3CF2CF2CF2-, particularly R2 is CF3.

In an embodiment of the invention as described anywhere herein, R3 is H or methyl.

In an embodiment of the invention as described anywhere herein, A is CR4a and R4a is methyl, ethyl, isopropyl and trifluoromethyl.

In an embodiment of the invention as described anywhere herein, A is CR4a and R4a is H.

In an embodiment of the invention as described anywhere herein, R4 is H or d-C4 alkyi optionally substituted by one or more halogen atoms. In an embodiment of the invention as described anywhere herein, R5 provides a heteroatom two carbons from the amide nitrogen, wherein the heteroatom is oxygen or nitrogen. In an embodiment of the invention as described anywhere herein, R4 is H, CrC4 alkyl optionally substituted by one or more halogen atoms or not present;

R5 is C"i-C4 alkoxy optionally substituted by one or more halogen atoms; -(CH2)m- NR 7R18; -(CH2)m-OR' ,or OH;

m is 0, or 1 ;

R6 is C"i-C4 alkyl optionally substituted by one or more halogen atoms; CrC4 alkoxy optionally substituted by one or more halogen atoms; OH; CN; halogen; -(C0-C4 alkyl)- C6-C14 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or

R4 and R5 together form an oxo group (C=0); or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents;

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.

In an embodiment of the invention as described anywhere herein,

A is CR4a;

R2 is C1 -C4 haloalkyl;

R3 is H;

R4 is H or Me;

R4a is H;

R5 is -(CH2)m-NR 7R18; -(CH2)m-OR'; or OH;

m is 0, or 1 ;

R6 is C-i-C4 alkyl optionally substituted by one or more halogen atoms; or R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H ; or C C4 alkyl optionally substituted by one or more halogen atoms.

In an embodiment of the invention as described anywhere herein,

A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4a is H ;

R4 and R5 together form an oxo group (C=0); and

R6 is C"i-C4 alkyl optionally substituted by one or more halogen atoms; C C4 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0- C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents. In an embodiment of the invention as described anywhere herein,

A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4 is H or Me;

R4a is H ;

R5 is -(CH2)m-N R 7R18; -(CH2)m-OR'; or OH ;

m is 0, or 1 ;

R6 is C"i-C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and R 7 and R 8 are each independently H ; or CrC4 alkyl optionally substituted by one or more halogen atoms.

In an embodiment of the invention as described anywhere herein,

A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4 is H or Me;

R4a is H ;

R5 is -(CH2)m-N R 7R18; -(CH2)m-OR; or OH ;

m is 0, or 1 ;

R6 is C C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H ; or CrC4 alkyl optionally substituted by one or more halogen atoms. In an embodiment of the invention as described anywhere herein,

A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4 is H or Me;

R4a is H ;

R5 is -N R 7R18; or OH ;

R6 is C-i-C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H ; or C C4 alkyl optionally substituted by one or more halogen atoms. In an embodiment of the invention as described anywhere herein,

A is CR4a;

R is C"i-C4 alkyl optionally substituted by one or more halogen atoms;

R2 is C1-C4 haloalkyl;

R3 is H;

R4 is H or Me;

R4a is H;

R5 is -NR 7R18; or OH;

R6 is C C4 alkyl optionally substituted by one or more halogen atoms; and

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.

In an embodiment of the invention as described anywhere herein,

Z is independently OH, d-C4 alkyl optionally substituted by one or more OH groups or NH2 groups, CrC4 alkyl optionally substituted by one or more halogen atoms, CrC4 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy, NR 9R21 , C(0)OR19, C(0)R19, SR 9, OR19, CN, N02, or halogen;

R 9 and R2 are each independently H; d-C4 alkyl; C3-C6 cycloalkyl; or d-C4 alkoxy-Cr C4 alkyl, wherein all alkyls are optionally substituted with halogens.

In an embodiment of the invention as described anywhere herein,

Z is independently OH, C C4 alkyl optionally substituted by one or more OH groups or NH2 groups, CrC4 alkyl optionally substituted by one or more halogen atoms, CrC4 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy, C(0)OR19, C(0)R19, OR19, CN, or halogen;

R 9 is H; d-C4 alkyl; C3-C6 cycloalkyl; or d-C4 alkoxy-C-i-C4 alkyl, wherein all alkyl are optionally substituted with halogens. In an embodiment of the invention as described anywhere herein,

Z is independently, d-C4 alkyl optionally substituted by one or more halogen atoms, Cr C4 alkoxy or halogen. In an embodiment of the invention as described anywhere herein,

the compound of formula I is a substantially pure enantiomers with the R configuration.

In an embodiment of the invention as described anywhere herein, the compound of formula I is a substantially pure enantiomers with the S configuration.

In an embodiment of the invention as described anywhere herein, the compounds of Formula I include compounds of Formula II:

Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001

In an embodiment of the invention as described anywhere herein, the compound is of formula II and R3 is H or methyl.

In an embodiment of the invention as described anywhere herein, the compound is of formula II and

A is CR4a;

R3 is H;

4a is H;

Figure imgf000014_0002
In an embodiment of the invention as described anywhere herein, the compound is of formula II and

Figure imgf000015_0001

In an embodiment of the invention as described anywhere herein, the compound is of formula II and

A is CR4a;

R3 is H;

4a is

Figure imgf000015_0002
In an embodiment of the invention as described anywhere herein, the compound is of formula II and

A is CR4a;

R3 is H;

R4a is H;

Figure imgf000016_0001

In an embodiment of the invention as described anywhere herein, the compound according to any one of embodiments 21 to 26, wherein

A is CR4a;

R3 is H;

4a is H;

Figure imgf000016_0002

In an embodiment of the invention as described anywhere herein, the compound is of formula II and A is CR4

R3 is H;

4a is H;

Figure imgf000017_0001

Another embodiment of the invention as defined above provides compounds according to Formula I and Formula II, or a pharmceutically acceptable salt thereof, represented by (S)-3-Amino-6-(2-methoxyethoxy)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5- (trifluoromethyl)picolinamide.

It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment are meant to be combined with any and all other elements from any of the embodiments to describe additional embodiments. It is understood by those skilled in the art that combinations of substituents where not possible are not an aspect of the present invention.

Especially preferred specific compounds of formula (I) or formula II are those described hereinafter in the Examples.

Definitions

Terms used in the specification have the following meanings: "Optionally substituted" means the group referred to can be substituted at one or more positions by any one or any combination of the radicals listed thereafter.

Optionally substituted by one or more Z groups" denotes that the relevant group may include one or more substituents, each independently selected from the groups included within the definition of Z. Thus, where there are two or more Z group substituents, these may be the same or different.

"Halo" or "halogen", as used herein, may be fluorine, chlorine, bromine or iodine.

"C-i-Ce-Alkyl", as used herein, denotes straight chain or branched alkyl having 1-8 carbon atoms. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as "Ci-C4-Alkyl" will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

"C-i-Ce-Alkoxy", as used herein, denotes straight chain or branched alkoxy having 1-8 carbon atoms. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as "C"i-C4-Alkoxy" will represent methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.

"C1-C4-Haloalkyl", as used herein, denotes straight chain or branched alkyl having 1-4 carbon atoms with at least one hydrogen substituted with a halogen. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as "C1-C4-Haloalkyl" will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with halogen, such as where the halogen is fluorine: CF3CF2-, (CF3)2CH-, CH3-CF2-, CF3CF2-, CF3, CF2H-, CF3CF2CHCF3 or CF3CF2CF2CF2-.

"C-i-Ce-hydroxyalkyl", as used herein, denotes straight chain or branched alkyl having 1- 8 carbon atoms with at least one hydrogen substituted with a hydroxy group. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as "C1-C4-hydroxyalkyl" will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with a hydroxy group.

The term 'C2-8 alkenyl' as used herein refers to a linear or branched saturated hydrocarbon group containing from 2 to 8 carbon atoms that contains at least one carbon to carbon double bond. Examples of such groups include ethenyl, propenyl, butenyl and pentenyl. Unless a particular structure is specified, the terms butenyl and pentenyl etc. include all possible E and Z isomers. The term "C2-8 alkynyl" as used herein refers to a linear or branched saturated hydrocarbon group containing from 2 to 8 carbon atoms that contains at least one carbon to carbon triple bond. Examples of such groups include ethynyl, propynyl, butynyl and pentynyl. The term 'C3-8 cycloalkyl' as used herein refers to a saturated monocyclic hydrocarbon ring of 3 to 6 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "alkylene" denotes a straight chain or branched saturated hydrocarbon chain containing between 1 and 8 carbon atoms. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"Amino-C-i-Ce-alkyl" and "amino-C-i-Cs-alkoxy" denote amino attached by a nitrogen atom to C C8-alkyl, e.g., NH2-(Ci-C8)-, or to C C8-alkoxy, e.g., NH2-(Ci-C8)-0-. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"CrCe-Alkylamino" and "di(C"rC8-alkyl)annino" denote Ci-C8-alkyl, as hereinbefore defined, attached by a carbon atom to an amino group. The CrC8-alkyl groups in di(CrC8-alkyl)amino may be the same or different. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"Amino-ihydroxyJ-C-i-Cs-alkyl" denotes amino attached by a nitrogen atom to CrC8-alkyl and hydroxy attached by an oxygen atom to the same CrC8-alkyl. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"Ci-C8-Alkylcarbonyl" and "Ci-C8-alkoxycarbonyl", as used herein, denote Ci-C8-alkyl or C-i-Ce-alkoxy, respectively, as hereinbefore defined, attached by a carbon atom to a carbonyl group. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"C3-C8-Cycloalkylcarbonyl", as used herein, denotes C3-C8-cycloalkyl, as hereinbefore defined, attached by a carbon atom to a carbonyl group. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"C7-C14-Aralkyl", as used herein, denotes alkyl, e.g., Ci-C4-alkyl, as hereinbefore defined, substituted by a C6-Ci0-aromatic carbocyclic group, as herein defined. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly.

"C3-C15-Cycloalkyl", as used herein, denotes a cycloalkyl having 3- to 15-ring carbon atoms that is saturated or partially saturated, such as a C3-C8-cycloalkyl. Examples of C3-Ci5-cycloalkyls include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl or a bicyclic group, such as bicyclooctyl, bicyclononyl including indanyl and indenyl and bicyclodecyl. If a different number of carbon atoms is specified, such as C6, then the definition is to be amended accordingly. "aryl" or "C6-Ci5-Aromatic carbocyclic group", as used herein, denotes an aromatic group having 6- to 15-ring carbon atoms. Examples of C6-C15-aromatic carbocyclic groups include, but are not limited to, phenyl, phenylene, benzenetriyl, naphthyl, naphthylene, naphthalenetriyl or anthrylene. If a different number of carbon atoms is specified, such as C-io, then the definition is to be amended accordingly.

"4- to 8-Membered heterocyclyl", "5- to 6- membered heterocyclyl", "3- to 10-membered heterocyclyl", "3- to 14-membered heterocyclyl", "4- to 14-membered heterocyclyl" and "5- to 14-membered heterocyclyl", refers, respectively, to 4- to 8-membered, 5- to 6- membered, 3- to 10-membered, 3- to 14-membered, 4- to 14-membered and 5- to 14-membered heterocyclic rings containing at least one ring heteroatom selected from the group consisting of nitrogen, oxygen and sulphur, which may be saturated, partially saturated or unsaturated (aromatic). The heterocyclyl includes single ring groups, fused ring groups and bridged groups. Examples of such heterocyclyls include, but are not limited to, furan, pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole, tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine, piperidine, pyrazine, oxazole, isoxazole, pyrazine, pyridazine, pyrimidine, piperazine, pyrrolidine, pyrrolidinone, morpholine, triazine, oxazine, tetrahyrofuran, tetrahydrothiophene, tetrahydrothiopyran,

tetrahydropyran, 1 ,4-dioxane, 1 ,4-oxathiane, indazole, quinoline, indazole, indole, 8-aza- bicyclo[3.2.1]octane or thiazole.

A second aspect of the invention provides a compound of Formula I or II as defined anywhere herein for use as a pharmaceutical.

A further aspect of the invention provides a compound of Formula I or II for use in the treatment of an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease or mucosal hydration. Such conditions include, for example, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced).

A still further aspect of the present invention provides for the use of a compound of formula (I) or (II), as defined in any of the aforementioned embodiments, in free or pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease or mucosal hydration.

An embodiment of the present invention provides for the use of a compound of formula (I) or (II), as defined in any of the aforementioned embodiments, in free or

pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of an inflammatory or allergic condition selected from cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced).

An embodiment of the present invention provides for the use of a compound of formula (I) or (II), as defined in any of the aforementioned embodiments, in free or

pharmaceutically acceptable salt form, for the manufacture of a medicament for the treatment of an inflammatory or allergic condition which is cystic fibrosis.

An embodiment of the present invention provides method for the prevention or treatment of a CFTR mediated condition or disease comprising administering an effective amount of at least one compound as described herein to a subject in need of such treatment. Such CFTR mediated condition or disease are selected from cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced).

Throughout this specification and in the claims that follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", should be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

As used herein, the term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate and trifluoroacetate salts.

Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and sulfosalicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine. The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.

Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.

Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley- VCH, Weinheim, Germany, 2002). Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.

Compounds of the invention, i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co- crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed. Suitable co-crystal formers include those described in WO

2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I).

As used herein, the term "isomers" refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms. Also as used herein, the term "an optical isomer" or "a stereoisomer" refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers" are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1 :1 mixture of a pair of enantiomers is a "racemic" mixture. The term is used to designate a racemic mixture where appropriate. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.

Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %

enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.

Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization. Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0,0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.

Since the compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1 %, more suitably at least 5% and preferably from 10 to 59% of a compound of the invention.

Compounds of the present invention are either obtained in the free form, or as a salt thereof.

When both a basic group and an acid group are present in the same molecule, the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, C, 3C, 4C, 5N, 8F 3 P, 32P, 35S, 36CI, 25l respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 3C, and 4C , are present. Such isotopically labeled compounds are useful in metabolic studies (with 4C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 8F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I) or (II). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium

incorporation), or at least 6633.3 (99.5% deuterium incorporation).

Isotopically-labeled compounds of formula (I) or (II) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, de- acetone, d6-DMSO. Compounds of the invention, i.e. compounds of formula (I) or formula (II) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) or formula (II) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) or formula (II) with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co- crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I) or formula (II). Synthesis

Generally, compounds according to Formula I or (II) can be synthesized by the routes described in Scheme 1 , 2 and 3 and the Examples.

When A is CH the pyridinyl moiety may be synthesized according to the general scheme 1 shown below.

Scheme 1

Figure imgf000029_0001

Figure imgf000029_0002

When A is nitrogen, the pyrazine moiety may be synthesized according to the general scheme 2 shown below.

Scheme 2

Figure imgf000029_0003

Figure imgf000030_0001

The right hand side of the moiety is typically added via an amide formation reaction as shown below in general scheme 3.

Scheme 3

Figure imgf000030_0002

HATU (2-(1 H-7-Azabenzotriazol-1-yl)-1 ,1 ,3,3-tetramethyl uronium hexafluorophosphate Methanaminium) is a peptide coupling agent. A skilled person would understand that other coupling agents cold possibly work.

The halogen group in the above schemes can be replaced with, alkyl, alkenyl and alkynyl using metal catalysed cross coupling reactions. . The schemes 4- 6 below are some representative examples.

Figure imgf000030_0003
Scheme 5

Figure imgf000031_0001

Figure imgf000031_0002

When R4a = alkyl, alkene, aryl and heteroaryl, compounds can be synthesized using

Figure imgf000031_0003

The alkyl, alkene and alkynyl, group is introduced selectively by reaction at the 2- chloropyridyl position using metal catalysed cross coupling reactions shown in schemes

7- 9 below.

Scheme 7

Figure imgf000031_0004
cheme 9

Figure imgf000032_0001

R4a group = alkyl, alkenyl, aryl, heteroaryl can be introduced at the 4-chloropyridyl position by a metal catalysed cross coupling reaction. Unsaturated aliphatic groups can

Figure imgf000032_0002

The skilled person will appreciate that the general synthetic routes detailed above show common reactions to transform the starting materials as required. The specific reaction conditions are not provided, but these are well known to those skilled in the art and appropriate conditions considered to be within the skilled person's common general knowledge.

The starting materials are either commercially available compounds or are known compounds and can be prepared from procedures described in the organic chemistry art.

Compounds of formula (I) or (II), in free form, may be converted into salt form, and vice versa, in a conventional manner understood by those skilled in the art. The compounds in free or salt form can be obtained in the form of hydrates or solvates containing a solvent used for crystallisation. Compounds of formula (I) or (II) can be recovered from reaction mixtures and purified in a conventional manner. Isomers, such as stereoisomers, may be obtained in a conventional manner, e.g., by fractional crystallisation or asymmetric synthesis from correspondingly asymmetrically substituted, e.g., optically active, starting materials. The compounds of formula (I) or (II) can be prepared, e.g., using the reactions and techniques described below and in the Examples. The reactions may be performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.

The various substituents on the synthetic intermediates and final products shown in the following reaction schemes can be present in their fully elaborated forms, with suitable protecting groups where required as understood by one skilled in the art, or in precursor forms which can later be elaborated into their final forms by methods familiar to one skilled in the art. The substituents can also be added at various stages throughout the synthetic sequence or after completion of the synthetic sequence. In many cases, commonly used functional group manipulations can be used to transform one

intermediate into another intermediate, or one compound of formula (I) or (II) into another compound of formula (I) or (II). Examples of such manipulations are conversion of an ester or a ketone to an alcohol; conversion of an ester to a ketone;

interconversions of esters, acids and amides; alkylation, acylation and sulfonylation of alcohols and amines; and many others. Substituents can also be added using common reactions, such as alkylation, acylation, halogenation or oxidation. Such manipulations are well-known in the art, and many reference works summarize procedures and methods for such manipulations. Some reference works which gives examples and references to the primary literature of organic synthesis for many functional group manipulations, as well as other transformations commonly used in the art of organic synthesis are March's Organic Chemistry, 5th Edition, Wiley and Chichester, Eds. (2001 ); Comprehensive Organic Transformations, Larock, Ed., VCH (1989); Comprehensive Organic Functional Group Transformations, Katritzky et al. (series editors), Pergamon (1995); and Comprehensive Organic Synthesis, Trost and Fleming (series editors), Pergamon (1991 ). It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. Multiple protecting groups within the same molecule can be chosen such that each of these protecting groups can either be removed without removal of other protecting groups in the same molecule, or several protecting groups can be removed using the same reaction step, depending upon the outcome desired. An authoritative account describing many alternatives to the trained practitioner is Greene and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons (1999).

Pharmacological activity

Having regard to their modulation of CFTR activity, compounds of formula (I), in free or pharmaceutically acceptable salt form, hereinafter alternately referred to as "agents of the invention", are useful in the treatment of conditions which respond to the modulation of CFTR activity, particularly conditions benefiting from mucosal hydration such as cystic fibrosis.

Diseases mediated by modulation of CFTR activity, include diseases associated with the regulation of fluid volumes across epithelial membranes. For example, the volume of airway surface liquid is a key regulator of mucociliary clearance and the maintenance of lung health. The modulation of CFTR activity will promote fluid accumulation on the mucosal side of the airway epithelium thereby promoting mucus clearance and preventing the accumulation of mucus and sputum in respiratory tissues (including lung airways). Such diseases include respiratory diseases, such as cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma, respiratory tract infections (acute and chronic; viral and bacterial) and lung carcinoma. Diseases mediated by modulation of CFTR activity also include diseases other than respiratory diseases that are associated with abnormal fluid regulation across an epithelium, perhaps involving abnormal physiology of the protective surface liquids on their surface, e.g., Sjogren's Syndrome, xerostomia (dry mouth) or keratoconjunctivitis sire (dry eye). Furthermore, modulation of CFTR activity in the kidney could be used to promote diuresis and thereby induce a hypotensive effect. Treatment in accordance with the invention may be symptomatic or prophylactic.

Asthma includes intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection. Treatment of asthma is also to be understood as embracing treatment of subjects, e.g., of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "wheezy infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics. (For convenience this particular asthmatic condition is referred to as "wheezy-infant syndrome".)

Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack, improvements in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e., therapy for or intended to restrict or abort symptomatic attack when it occurs, e.g., anti-inflammatory (e.g., cortico-steroid) or bronchodilatory. Prophylactic benefit in asthma may, in particular, be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognized asthmatic syndrome, common to a substantial percentage of asthmatics and characterized by asthma attack, e.g., between the hours of about 4-6 am, i.e., at a time normally substantially distant from any previously administered symptomatic asthma therapy. Chronic obstructive pulmonary disease includes chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular, other inhaled drug therapy. The invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.

Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles. There are many causes of dry eye, some of which include age, laser eye surgery, arthritis, medications, chemical/thermal burns, allergies and diseases, such as cystic fibrosis and Sjogren's Syndrome.

Increasing anion secretion via CFTR would enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease.

Sjogren's Syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including eye, mouth, skin, respiratory tissue, liver, vagina and gut. Symptoms include dry eye, dry mouth and dry vagina, as well as lung disease. The disease is also associated rheumatoid arthritis, systemic lupus, systemic sclerosis and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited.

Modulators of CFTR activity may hydrate the various organs affected by the disease and help to alleviate the associated symptoms. The suitability of CFTR activity modulators as a treatment of a disease benefiting from mucosal hydration may be tested by determining the movement of chloride ions in a suitable cell-based assay. For example single cells or confluent epithelia, endogenously expressing or engineered to overexpress CFTR can be used to assess channel function using electrophysiological techniques or ion flux studies. See methods described in: Hirsh et al., J Pharm Exp Ther (2004); Moody et al., Am J Physiol Cell Physiol (2005).

CFTR activity modulators, including the compounds of formula (I), are also useful as co- therapeutic agents for use in combination with other drug substances, such as antiinflammatory, bronchodilatory, antihistamine or anti-tussive drug substances, particularly in the treatment of cystic fibrosis or obstructive or inflammatory airways diseases such as those mentioned hereinbefore, e.g., as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. The compounds of Formula (I) or (II) may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly, the invention includes as a further aspect a combination of a CFTR activity modulator with osmotic agents (hypertonic saline, dextran, mannitol, Xylitol), ENaC blockers, an anti-inflammatory, bronchodilatory, antihistamine, anti-tussive, antibiotic and/or DNase drug substance, wherein the CFTR activity modulator and the further drug substance may be in the same or different pharmaceutical composition.

Suitable antibiotics include macrolide antibiotics, e.g., tobramycin (TOBI™).

Suitable DNase drug substances include dornase alfa (Pulmozyme™), a highly-purified solution of recombinant human deoxyribonuclease I (rhDNase), which selectively cleaves DNA. Dornase alfa is used to treat cystic fibrosis.

Other useful combinations of CFTR activity modulators with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g., CCR-1 , CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1 , CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists, such as Schering-Plough antagonists SC- 351125, SCH-55700 and SCH-D; Takeda antagonists, such as A/-[[4-[[[6,7-dihydro-2-(4- methyl-phenyl)-5 -/-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro- A/,A/-dimethyl-2H-pyran-4-amin-ium chloride (TAK-770); and CCR-5 antagonists described in USP 6,166,037 (particularly claims 18 and 19), WO 00/66558 (particularly claim 8), WO 00/66559 (particularly claim 9), WO 04/018425 and WO 04/026873.

Suitable anti-inflammatory drugs include steroids, in particular, glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679 (especially those of Examples 3, 1 1 , 14, 17, 19, 26, 34, 37, 39, 51 , 60, 67, 72, 73, 90, 99 and 101 ), WO 03/35668, WO 03/48181 , WO 03/62259, WO 03/64445, WO 03/72592, WO 04/39827 and WO 04/66920; non-steroidal glucocorticoid receptor agonists, such as those described in DE 10261874, WO

00/00531 , WO 02/10143, WO 03/82280, WO 03/82787, WO 03/86294, WO 03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO 04/19935 and WO 04/26248; LTD4 antagonists, such as montelukast and zafirlukast; PDE4 inhibitors, such as cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden),V-1 1294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma),

PD189659/PD168787 (Parke-Davis), AWD-12-281 (Asia Medica), CDC-801 (Celgene), SelCID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751 , WO 98/18796, WO 99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO 04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451 , WO 04/018457, WO 04/018465, WO 04/018431 , WO 04/018449, WO 04/018450, WO 04/018451 , WO 04/018457, WO 04/018465, WO 04/019944, WO 04/019945, WO 04/045607 and WO 04/037805; adenosine A2B receptor antagonists such as those described in WO 02/42298; and beta-2 adrenoceptor agonists, such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol, carmoterol or pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula (I) of WO 00751 14, which document is incorporated herein by reference, preferably compounds of the Examples thereof, especially a compound of formula:

Figure imgf000038_0001

corresponding to indacaterol or pharmaceutically acceptable salts thereof, as well as compounds (in free or salt or solvate form) of formula (I) of WO 04/16601 , and also compounds of EP 1440966, JP 05025045, WO 93/18007, WO 99/64035,

USP 2002/0055651 , WO 01/42193, WO 01/83462, WO 02/66422, WO 02/70490, WO 02/76933, WO 03/24439, WO 03/42160, WO 03/42164, WO 03/72539, WO

03/91204, WO 03/99764, WO 04/16578, WO 04/22547, WO 04/32921 , WO 04/33412, WO 04/37768, WO 04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO

04/45618, WO 04/46083, WO 04/80964, WO 04/108765 and WO 04/108676.

Suitable bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in EP 424021 , USP 3,714,357, USP 5,171 ,744, WO 01/041 18, WO 02/00652, WO 02/51841 , WO 02/53564, WO 03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO 04/018422 and WO 04/05285. Suitable dual anti-inflammatory and bronchodilatory drugs include dual beta-2 adrenoceptor agonist/muscarinic antagonists such as those disclosed in USP

2004/0167167, WO 04/74246 and WO 04/74812.

Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine, as well as those disclosed in JP 2004107299, WO

03/099807 and WO 04/026841. The invention includes as a further aspect a combination of a CFTR activity modulator with a CFTR corrector, wherein the CFTR activity modulator and the CFTR corrector may be in the same or different pharmaceutical composition. Suitable CFTR correctors include VX-809

Figure imgf000039_0001

Me and

VX-661

Figure imgf000040_0001

In accordance with the foregoing, the invention also provides as a further aspect a method for the treatment of a condition responsive to modulation of CFTR activity, e.g., diseases associated with the regulation of fluid volumes across epithelial membranes, particularly an obstructive airways disease, which comprises administering to a subject, particularly a human subject, in need thereof a compound of formula (I) or (II), in free form or in the form of a pharmaceutically acceptable salt. In another aspect the invention provides a compound of formula (I) or (II), in free form or in the form of a pharmaceutically acceptable salt, for use in the manufacture of a medicament for the treatment of a condition responsive to modulation of CFTR activity, particularly an obstructive airways disease, e.g., cystic fibrosis and COPD. The agents of the invention may be administered by any appropriate route, e.g. orally, e.g., in the form of a tablet or capsule; parenterally, e.g., intravenously; by inhalation, e.g., in the treatment of an obstructive airways disease; intranasally, e.g., in the treatment of allergic rhinitis; topically to the skin; or rectally. In a further aspect, the invention also provides a pharmaceutical composition comprising a compound of formula (I), in free form or in the form of a pharmaceutically acceptable salt, optionally together with a pharmaceutically acceptable diluent or carrier therefor. The composition may contain a co-therapeutic agent, such as an anti-inflammatory, broncho-dilatory, antihistamine or anti-tussive drug as hereinbefore described. Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art. Thus oral dosage forms may include tablets and capsules. Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g., patches. Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations. When the composition comprises an aerosol formulation, it preferably contains, e.g., a hydro-fluoro-alkane (HFA) propellant, such as HFA134a or HFA227 or a mixture of these, and may contain one or more co-solvents known in the art, such as ethanol (up to 20% by weight), and/or one or more surfactants, such as oleic acid or sorbitan trioleate, and/or one or more bulking agents, such as lactose. When the composition comprises a dry powder formulation, it preferably contains, e.g., the compound of formula (I) or (II) having a particle diameter up to 10 microns, optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance deterioration due to moisture, e.g., magnesium stearate. When the composition comprises a nebulised formulation, it preferably contains, e.g., the compound of formula (I) or (II) either dissolved, or suspended, in a vehicle containing water, a co-solvent, such as ethanol or propylene glycol and a stabilizer, which may be a surfactant.

Further aspects of the invention include:

(a) a compound of formula (I) or (II) in inhalable form, e.g., in an aerosol or other atomisable composition or in inhalable particulate, e.g., micronised form;

(b) an inhalable medicament comprising a compound of formula (I) or (II) in inhalable form;

(c) a pharmaceutical product comprising a compound of formula (I) in inhalable form in association with an inhalation device; and

(d) an inhalation device containing a compound of formula I or II in inhalable form.

Dosages of compounds of formula (I) or (II) employed in practicing the present invention will of course vary depending, e.g., on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for administration by inhalation are of the order of 0.005-10 mg, while for oral administration suitable daily doses are of the order of 0.05-100 mg.

Pharmaceutical Use and Assay Compounds of formula (I) or (II) and their pharmaceutically acceptable salts, hereinafter referred to alternatively as "agents of the invention", are useful as pharmaceuticals. In particular, the compounds are suitable CFTR activity modulators and may be tested in the following assays.

Membrane potential assay

CFTR activity can be quantified by measuring the transmembrane potential. The means for measuring the transmembrane potential in a biological system can employ a number of methods including electrophysiological and optical fluorescence-based membrane potential assays.

The optical membrane potential assay utilises a negatively charged potentiometric dye, such as the FLIPR membrane potential dye (FMP) (see Baxter DF, Kirk M, Garcia AF, Raimondi A, Holmqvist MH, Flint KK, Bojanic D, Distefano PS, Curtis R, Xie Y. Ά novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels.' J Biomol Screen. 2002 Feb;7(1 ):79-85) which when extracellular is bound to a quenching agent . Upon cellular depolarisation the negatively charged dye redistributes to the intracellular compartment, unbinding from the membrane impermeant quench agent, yielding an increase in fluorescence. This change in fluorescence is proportional to the change in transmembrane potential which can result from the activity of CFTR.

The changes in fluorescence can be monitored in real time by an appropriately equipped fluorescence detector such as the FLIPR (fluorometric imaging plate reader) in 96 or 384-well microtitre plates. Cell culture:

Chinese hamster ovary (CHO) cells stably expressing the F508-CFTR channel were used for membrane potential experiments. Cells were maintained at 37 °C in 5% v/v C02 at 100% humidity in Modified Eagles medium (MEM) supplemenetd with 8% v/v foetal calf serum, 100μg/ml methotrexate and 100U/ml penicillin/streptomycin. Cells were grown in 225 cm2 tissue culture flasks. For membrane potential assays cells were seeded into 96 well plates at 40,000 cells per well, allowed to adhere and then maintained at 26 °C for 48h to facilitate channel insertion. Potentiator assay:

The membrane potential screening assay utilised a low chloride ion containing extracellular solution (~5mM) combined with a double addition protocol. The first addition was of buffer with or without test compound followed 5 minutes later by an addition of forskolin (1-20 μΜ) - this protocol favours maximum chloride efflux in response to

F508-CFTR activation. The F508-CFTR mediated chloride ion efflux leads to a membrane depolarisation which is optically monitored by the FMP dye.

Solutions:

Low chloride extracellular (mM): 120 Na-gluconate, 1.2 CaCI2, 3.3 KH2P04, 0.8 K2HP04, 1.2 MgCI2, 10.0 D-glucose, 20.0 HEPES, pH 7.4 with NaOH

FMP dye: made up as per manufacturers' instructions in low chloride extracellular solution detailed above, at 10x final concentration, and stored as 1 ml. aliquots at -20°C. lonWorks Quattro assay:

CFTR activity can also be quantified electrophysiologically using the whole-cell configuration of the patch clamp technique (Hamill et al Pflugers Acrhive 1981 ). This assay directly measures the currents associated with chloride flow through CFTR channels whilst either maintaining or adjusting the transmembrane voltage. This assay can use either single glass micropipettes or parallel planar arrays to measure CFTR activity from native or recombinant cell systems. Currents measured using parallel planar arrays can be quantified using an appropriately equipped instrument such as the lonWorks Quattro (Molecular Devices) or the Qpatch (Sophion). The Quattro system can measure CFTR currents from either a single cell per recording well (HT configuration) or alternatively from a population of 64 cells per well (Population Patch Clamp PPC) (Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J. 'Population patch clamp improves data consistency and success rates in the measurement of ionic currents.' J Biomol Screen. 2006 Aug;1 1 (5):488-96). Cell culture:

Chinese hamster ovary (CHO) cells stably expressing the F508-CFTR channel were used for lonWorks Quattro experiments. Cells were maintained at 37 °C in 5% v/v C02 at 100% humidity in D-MEM supplemented with 10 % (v/v) FCS, 100 U/mL Penicillin/Streptomycin, 1 % (v/v) NEAA, 1 mg/ml Zeocin and 500 ug/ml Hygromycin B. For experiments cells were grown in 225 cm2 tissue culture flasks until near confluence and then cultured at 26 °C for 48-72h to facilitate channel insertion. Cells were removed from the flask and resuspended in either extracellular recording solution for immediate experimentation or alternatively in growth medium supplemented with 10% v/v DMSO and frozen to -80°C as 1-2 ml. aliquots for use at a later date.

Potentiator assay:

Cells, at a density of 1.5-3 million per ml_, were placed on the Quattro system, added to the planar patch array and seals allowed to establish for 5-10 mins. After assessing seal resistances (commonly >50 M ), whole-cell access was obtained by perforation with 100 μg/mL amphotericin B. Baseline currents were measured by a pre-compound scan obtained by application of a voltage ramp from -100 to +100 mV. This was followed by addition of either buffer or test compound diluted in the extracellular solution

supplemented with 20 μΜ forskolin, to each of the 384 wells of the planar parch array. After incubation step (5-20 minutes) the post-compound currents were measured again by application of a voltage ramp from -100 to +100 mV. The difference in currents between the pre- and post-compound scans defined the efficacy of CFTR potentiation. Solutions:

Extracellular solution (ECS) : 145 mM NaCI, 4 mM CsCI, 5 mM D-glucose, 10 mM TES, 1 mM CaCI2, 1 mM MgCI2, pH 7.4 NaOH

Intracellular buffer (ICS): 1 13 mM L-Aspartic acid, 113 mM CsOH, 27 mM CsCI, 1 mM NaCI, 1 mM MgCI2, 1 mM EGTA, 10 mM TES. pH 7.2 with CsOH. Filter sterilized before use.

Ion transport assay:

Another method to measure CFTR function is Ussings chamber short circuit current measurement. Engineered or native epithelial cells are grown to confluent monolayer on a semi-permeable filter and sandwiched between two perspex blocks. The flow of chloride ions via CFTR from one side of the epithelia to the other can be quantified by measuring the flow of current whilst maintaining the transepithelial potential at OmV. This is achieved using KCI filled agar-based electrodes to both clamp the cellular monolayer and measure the flow of currents.

Cell culture:

FRT cells stably expressing AF508-CFTR were cultured on plastic in Coon's modified F- 12 medium supplemented with 32mM NaHC03, 10% v/v fetal bovine serum, 2 mM L- glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and 30 μg/mL hygromycin B as the growth medium. For Ussing chamber experiments, the cells were grown as polarized epithelia on Snapwell permeable support inserts (500000 cells/insert in growth medium) and cultured for 7 to 9 days. The inserts were fed with fresh Coon's modified F-12 growth medium every 48 hours, and 24 hours prior to Ussing chamber experiment. To increase the AF508 CFTR protein expression at the cell surface, plates were incubated at 27°C for 48h before performing an Ussing chamber experiment. Potentiator assay:

Fischer Rat Thyroid (FRT) epithelial cells, stably expressing human AF508-CFTR were used as monolayer cultures on permeable supports. CI" current was measured using the short circuit current technique, under an imposed basolateral to apical CI" gradient in Ussing chambers. To measure stable CI" currents, FRT cells were cultured for 48h at 27°C to facilitate the insertion of AF508 CFTR into the plasma membrane. Ussing chamber studies were likewise conducted at 27°C . Under these conditions, the effects of cumulative additions of test compounds on AF508 CFTR currents could be quantitated with both potency and efficacy endpoints. Compounds were added to both the apical and basloalteral sides subsequent to addition of 10μΜ forskolin. Efficacy of compounds was compared to a known potentiator such as gensitein.

Solutions:

Basolateral Ringer solution (mM): 126 NaCI, 24 NaHC03, 0.38 KH2P04, 2.13 K2HP04, 1 MgS04, 1 CaCI2 and 10 glucose.

Apical Ringer solution (mM): 140 Na-gluconate, 1 MgS04, 2 CaCI2, 1 HCI, 10 glucose and 24 NaHC03.

Compounds can also be tested for their ability to stimulate insertion of AF508 CFTR into the cell membrane using the above assays. For these assays the protocols were identical other than cells were not cultured at low temperature (26 or 27°C) but instead incubated with test compounds for 12-24 h prior to assay.

Compounds of the Examples, herein below, generally have EC50 values in the data measurements described above below 10 μΜ. Table 1 provides a list of representative compounds with their EC50 value.

Table 1.

Figure imgf000046_0001
The invention is illustrated by the following Examples. Examples

General Conditions:

Mass spectra were run on LCMS systems using electrospray ionization. These were either Agilent 1 100 HPLC/Micromass Platform Mass Spectrometer combinations or Waters Acquity UPLC with SQD Mass Spectrometer. [M+H]+ refers to mono-isotopic molecular weights.

NMR spectra were run on open access Bruker AVANCE 400 NMR spectrometers using ICON-NMR. Spectra were measured at 298K and were referenced using the solvent peak.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade.

If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR.

Abbreviations used are those conventional in the art. If not defined, the terms have their generally accepted meanings.

Abbreviations:

app apparent

br broad d doublet

dd doublet of doublets

DCM dichloromethane

DIPEA diisopropylethylamine

DMF N,N-dimethylformamide

DMSO dimethylsulfoxide

EtOAc ethyl acetate

h hour(s)

HATU 2-(7-Aza-1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium

hexafluorophosphate

HPLC high pressure liquid chromatography

Int. intermediate

LC-MS liquid chromatography and mass spectrometry

MeOH methanol

MS mass spectrometry

m multiplet

min minutes

ml milliliter(s)

m/z mass to charge ratio

NMR nuclear magnetic resonance

ppm parts per million

PS polymer supported

RT room temperature

Rt retention time

s singlet

SCX-2 strong cation exchange (e.g. Isolute® SCX-2 columns from Biotage) t triplet

TFA trifluoroacetic acid

THF tetrahydrofuran

Referring to the examples that follow, compounds of the preferred embodiments were synthesized using the methods described herein, or other methods, which are known in the art. The various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Unless otherwise stated, all starting materials are obtained from commercial suppliers and used without further purification. Salts may be prepared from compounds by known salt-forming procedures.

It should be understood that the organic compounds according to the preferred embodiments may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embodiments encompasses any tautomeric form of the drawn structure.

If not indicated otherwise, the analytical LC-MS conditions are as follows:

Method 2minl_owpH:

Column: Waters Acq uity CSH 1.7pm, 2.1 x 50mm

Temperature: 50 °C

Mobile Phase: A: Water +0.1 % Formic Acid B: Acetonitrile +0.1 % Formic

Acid

Flow rate: 1.0mL/min

Gradient: O.Omin 5%B, 0.2-1.3min 5-98%B, 1.3-1.55min 98%B, 1.55-

1.6min 98-5%B

Method 10minLowpH

Column: Waters Acq uity CSH 1.7pm, 2.1 x 100mm

Temperature: 50 °C

Mobile Phase: A: Water +0.1 % Formic Acid B: Acetonitrile +0.1 % Formic

Acid

Flow rate: 0.7mL/min

Gradient: O.Omin 2%B, 0.5-8.0min 2-98%B, 8.0-9.0min 98%B, 9.0-

9.1 min 98-2%B Method 10minl_C_v002

Column Waters BEH C18 50x2.1 mm, 1.7 μηη

Column Temperature 50 °C

Eluents A: H20, B: methanol, both containing 0.1 % TFA

Flow Rate 0.8 mL/min

Gradient 0.20 min 5% B; 5% to 95% B in 7.80 min, 1.00 min 95% B

Method 10minl_C_v003

Column Waters BEH C18 50x2.1 mm, 1.7 μηη

Column Temperature 50 °C

Eluents A: H20, B: acetonitrile, both containing 0.1 % TFA Flow Rate 0.8 mL/min

Gradient 0.20 min 5% B; 5% to 95% B in 7.80 min, 1.00 min 95% B

Method 2minl_C_v002

Column Waters BEH C18 50x2.1 mm, 1.7 μηη

Column Temperature 50 °C

Eluents A: H20, B: methanol, both containing 0.1 % TFA

Flow Rate 0.8 mL/min

Gradient 0.20 min 5% B; 5% to 95% B in 1 .30 min, 0.25 min 95% B

Method 2minLC_v003

Column Waters BEH C18 50x2.1 mm, 1.7 μηη

Column Temperature 50 °C

Eluents A: H20, B: acetonitrile, both containing 0.1 % TFA Flow Rate 0.8 mL/min

Gradient 0.20 min 5% B; 5% to 95% B in 1 .30 min, 0.25 min 95% B

Example compounds of the present invention include:

Preparation of Final Compounds Further compounds of formula (I) where R is not alkyl, alkenyl or alkynyl but where the scope of R2, R3, R4, R5 and R6 is similar to this application are disclosed in patent application WO201 1/1 13894 (PCT/EP201 1/054038). Example 1.0

(S)-3-Amino-6-(3-(dimethylamino)propyl)-N-(3,3,3-trifluoro-2-hydroxy-2- methylpropyl)-5-(trifluoromethyl)picolinamide

Figure imgf000050_0001

Step 1 : Methyl 3-amino-6-(3-(dimethylamino)prop-1-ynyl)-5-(trifluoromethyl)picolinate A mixture comprising 3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester (Intermediate A step 4) (300 mg, 1.003 mmol), N,N-dimethylprop-2-yn-1- amine (0.1 19 ml, 1.104 mmol) and copper(l) iodide (3.82 mg, 0.020 mmol) in 1 ,4- dioxane (1.500 ml) under nitrogen was treated with triethylamine (1.818 ml, 13.04 mmol) followed by Pd(PPh3)2CI2 (14.08 mg, 0.020 mmol) and stirred at 100°C for 15 minutes. A further portion of Pd(PPh3)2CI2 (14.08 mg, 0.020 mmol) was added and stirring continued at 100°C for 15 minutes. The mixture was poured into water and extracted with EtOAc. The organic portion was separated and washed with water, brine and dried using a phase separating column. The mixture was acidified to pH1 using 1 M HCI and the aqueous portion was separated and basified to pH7 using saturated sodium bicarbonate solution. The mixture was extracted with EtOAc and the combined organic extracts were washed with brine and dried using a phase separating column. The solvent was removed under reduced pressure to afford the title compound;

LC-MS Rt = 0.51 min [M+H]+ 302.4 ; Method 2minl_owpH.

Step 2: Methyl 3-amino-6-(3-(dimethylamino)propyl)-5-(trifluoromethyl)picolinate

Methyl 3-amino-6-(3-(dimethylamino)prop-1-ynyl)-5-(trifluoromethyl)picolinate (step 1 ) (136 mg, 0.451 mmol) in EtOH (5 ml) was pumped through a Pd/C (10%) cartridge at RT at a flow rate of 1 ml/min for 3 hours. The solvent was removed under reduced pressure to afford the title compound;

LC-MS Rt = 0.57 min [M+H]+ 306.2 ; Method 2minl_owpH.

Step 3: 3-Amino-6-(3-(dimethylamino)propyl)-5-(trifluoromethyl)picolinic acid sodium salt Methyl 3-amino-6-(3-(dimethylamino)propyl)-5-(trifluoromethyl)picolinate (step 2)(1 13 mg, 0.370 mmol) in THF (740 μΙ_) in NaOH (185 μΙ, 0.370 mmol) was strirred at RT for 4 hours. The solvent was removed under reduced pressure to afford the title compound; LC-MS Rt = 2.61 min [M+H]+ 292.5 ; Method l OminLowpH.

Stee_4: (S)-3-Amino-6-(3-(dimethylamino)propyl)-N-(3,3,3-trifluoro-2-hydroxy-2- methylpropyl)-5-(trifluoromethyl)picolinamide

The title compound was prepared from 3-amino-6-(3-(dimethylamino)propyl)-5- (trifluoromethyl)picolinic acid sodium salt (step 3) and (S)-3-amino-1 ,1 ,1-trifluoro-2- methylpropan-2-ol (Intermediate C) analogously to Example 4.0 step 6;

LC-MS Rt = 0.69 min [M+H]+ 418.6 ; Method 2minl_owpH.

1 H NMR, (400 MHz, DMSO-d6) δ 8.5 (1 H, t), 7.5 (1 H, s), 7.0 (2H, broad), 6.3 (1 H, s), 3.7 (1 H, mult), 3.5 (1 H, mult), 2.7 (2H, t), 2.3 (2H, t), 2.1 (6H, s), 1.8 (2H, mult), 1.3 (3H, s)

Preparation of Intermediates

Intermediate A

3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid

Figure imgf000051_0001

Step 1 : 2-Bromo-3-nitro-5-trifluoromethvl-pvridine

3-Nitro-5-(trifluoromethyl)pyridin-2-ol (31.00 g, 149 mmol) was dissolved in acetonitrile

(250 ml) to give a dark brown solution. Phosphorus(V) oxybromide (85 g, 298 mmol) was added and the mixture was heated at reflux for 4 hours and then stirred at RT overnight.

The reaction mixture was quenched by pouring into vigorously stirring water (600 ml) containing sodium hydrogencarbonate (1 10 g). The dark brown mixture was extracted with DCM (3 x 200 ml) and the organic phase was washed with water (200 ml) and brine

(100ml), dried (MgS04) and concentrated under reduced pressure to afford the title product as a brown oil.

H-NMR: [400MHz, CDCI3, δ 8.87 (1 H, d, J = 1.4Hz, ArH), 8.39 (1 H, d, J = 1.9Hz, ArH). Step 2: 3-Nitro-5-trifluoromethvl-pyridine-2-carbonitrile 2- Bromo-3-nitro-5-trifluoromethyl-pyridine (10.00 g, 36.87 mmol) was dissolved in toluene (250 ml) with stirring to give a pale yellow solution. Tetrabutylammonium bromide (11.90 g, 36.9 mmol) was added followed by copper(l) cyanide (9.92 g, 1 1 1 mmol) and the mixture was heated at reflux for 9 h. After cooling to RT, the reaction mixture was partitioned between water (750 ml) and EtOAc (750 ml). The organic fractions were combined, washed with water (2 x 250 ml), brine (100 ml), dried (MgS04) and concentrated under reduced pressure to afford the title product.

H-NMR: [400MHz, DMSO-d6] δ 9.55 (1 H, m, ArH), 9.24 (1 H, m, ArH)

Step 3: 3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester

3-Nitro-5-trifluoromethyl-pyridine-2-carbonitrile (6.5 g, 29.9 mmol) was dissolved in

EtOAc (150 ml) to give a pale yellow solution. 10 % Palladium on activated carbon (3.19 g, 2.99 mmol) was added and the reaction mixture stirred under an atmosphere of hydrogen for 18 hours. The reaction mixture was filtered and concentrated under reduced pressure. The crude residue was dissolved in HCI cone. (45 ml) and heated to reflux for 24 hours. The reaction mixture was allowed to cool to RT and concentrated under reduced pressure. The solid was dissolved in MeOH (200 ml) and sulfuric acid (8 ml) was added. The resulting solution was heated at reflux for 84 hours. The reaction was allowed to cool to RT, then neutralised by addition of 10% NaHC03(aq) (600 ml). The product was extracted into DCM (3 x 200 ml) and the combined organic phases were washed with water (200 ml), brine (50 ml), dried (MgS04) and concentrated under reduced pressure. The resulting solid was purified by chromatography on silica : Eluant gradient: iso-hexane (500ml), 10% EtOAc in isohexane (1000 ml), 20% EtOAc in iso- hexane (1500 ml) to afford the titled compound as a pale yelow solid

H-NMR: [400MHz, DMSO-d6] δ 8.13 (1 H, d, J = 1.7Hz, ArH), 7.60 (1 H, d, J = 1.3Hz, ArH), 7.01 (2H, br, NH2), 3.85 (3H, s, ArOCH3), m/z 221.1 [M+H]+

Step 4 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester

3- Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester (9.49 g, 43.16 mmol) was dissolved in water (300 ml). Sulfuric acid (4.60 ml, 86 mmol) was added followed by dropwise addition over 30 minutes of a solution of bromine (2.222 ml, 43.1 mmol) in acetic acid (29.6 ml, 517 mmol). The reaction mixture was stirred at RT for 18 hours. A further 100 ml of water was added, followed by a further 0.25 equivalents of the bromine/AcOH mixture (550 μΙ bromine in 7.4 ml AcOH) and the reaction mixture stirred at RT for an additional 90 minutes. The reaction mixture was diluted with water (500 ml) and neutralised by addition of solid NaHC03 (-85 g). The suspension was extracted with DCM (3 x 300 ml) and the combined organic phases washed with sat.NaHC03(aq) (250 ml), water (250 ml) and brine (100 ml), dried (MgS04) and concentrated under reduced pressure. The crude material was recrystallised from boiling MeOH (-300 ml) to give the title product as a pale orange solid:

LC-MS m/z 301.0 [M+H]+

H-NMR (400MHz, DMSO-d6)5 7.77 (1 H, s, ArH), 7.17 (2H, s, NH2), 3.86 (3H, s, ArC02CH3).

Step 5: 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid

3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester (1.40 g, 4.68 mmol) was suspended in MeOH (15 ml); Sodium hydroxide (2.0 M aqueous solution) (14.04 ml, 28.1 mmol) was added and the suspension was stirred at RT overnight. The reaction mixture was concentrated under reduced pressure and the resulting residue was dissolved in water (100 ml) and then acidifed by the addition of 5.0M HCI(aq). The product was extracted into ethyl acetate (2 x 75 ml) and the combined organic extracts were washed with water (50 ml), brine (25 ml), dried (MgS04) and concentrated under reduced pressure to afford the title product as a yellow solid.

H-NMR: 9400MHz, DMSO-d6) δ 13.24 (1 H, br s, C02H), 7.74 (1 H, s, ArH), 7.17 92H, br s ArNH2). m/z 285.1 , 287.1 [M+H]+

Intermediate C

(S)-3-Amino-1 ,1 ,1 -trifluoro-2-methylpropan-2-ol hydrochloride

Figure imgf000053_0001

Route 1 :

Step 1 : Benzyl 3,3,3-trifluoro-2-hydroxy-2-methylpropylcarbamate

To a stirring suspension of amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol hydrochloride (Intermediate D) (1.5 g, 8.35 mmol) in DCM (50 ml) was added TEA 93.54 g, 35.0 mmol) followed by benzyl 2,5-dioxopyrrolidin-1-yl carbonate (1.983 g, 7.96 mmol). The mixture was stirred at RT for 6 hours and then diluted with water. The organic portion was separated using a phase separator and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-70% EtOAc in iso-hexane afforded the title product;

LC-MS: Rt 1.05 min; MS m/z 278.1 [M+H]+; Method 2minl_C_v003.

1 H NMR (400 MHz, DMSO-d6) δ 7.34 (6H, m), 5.98 (1 H, s), 5.05 (2H, s), 3.31 (1 H, m), 3.18 (1 H, m), 1.21 (3H. s)

Step 2: Separation of Enantiomers of benzyl 3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate

Benzyl 3,3,3-trifluoro-2-hydroxy-2-methylpropylcarbamate (1.7 g) was dissolved in 2- propanol (10 ml) and purified using the following chromatographic conditions:

Mobile Phase: 10% 2-propanol / 90% C02

Column: 2 x Chiralcel OJ-H, 250 x 10 mm id, 5 μηη (columns coupled in series) Detection: UV @ 220nm

Flow rate: 10 ml/min

Sample concentration: 1.7 g in 10 ml 2-propanol

Injection volume: 75μΙ

First eluted peak: Rt = 6.94 minutes (R)-benzyl 3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate

Second eluted peak: Rt = 8.04 minutes (S)-benzyl 3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate

Step 3: (S)-3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol hydrochloride

A mixture comprising (S)-benzyl 3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate in EtOH(165 ml) was pumped through a H-Cube (hydrogenation reactor, 1-2 ml/min, 1 bar pressure, RT) for 8 hours using a 10% palladium on carbon catalyst cartridge. 1.25 M HCI in methanol (130 ml) was added to the mixture was stirred for 30mins. The solvent was removed under reduced pressure azeotroping with MeCN to afford the title product as a white powder; 1 H NMR (400 MHz, DMSO-d6) δ 8.3 (3H, broad), 6.8 (1 H, s), 3.0 (2H, s), 1.5 (3H, s). Alternatively, racemic 3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol can be resolved into separate enantiomers by recrystallistion with either (S)-Mandelic acid or L-tartaric acid in isopropanol or ethanol to afford (S)-3-Amino-1 , 1 , 1-trifluoro-2-methylpropan-2-ol: Route 2:

Step 1 : (S)-3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol L-tartrate salt

3-Amino-1 ,1 ,1-trifluoro-2-methyl-propan-2-ol (40 g, 280 mmol) and L-(+)-tartaric acid (42.0 g, 280 mmol) were dissolved in EtOH + 4 % H20 (1398 ml) and warmed to 65 °C in an oil bath at 80 °C over 30 minutes. The resultant solution was left to cool and crystallise overnight at room temperature. The white precipitate was collected by filtration and dried in a vacuum oven at 40 °C for 2 hours to afford the title compound (22.5 g, 27.5 %, enantiomeric excess (e.e) = 76.6 %). A second crystallization was carried out as follows to enrich the e.e. (S)-3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol L-tartrate salt (22.5 g, 76.7 mmol) was dissolved in EtOH + 4 % H20 (384 ml, 0.2 M) at 80 °C and left to crystallise overnight. The white precipitate was collected by filtration and allowed to dry at RT overnight (18.4 g, e.e. = 94.4 %). A third crystallisation was carried out; (S)- 3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol L-tartrate salt (18.4 g, 62.8 mmol) was heated in EtOH + 4 % H20 (314 ml, 0.2 M) at 80 °C for 2 h and allowed to cool and crystallize overnight. The white precipitate was collected by filtration and dried in a vacuum oven at 50 °C for 5 hours to afford the title compound; e.e. = 97.4 %.

Step 2: (S)-3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol

To a suspension of Isolute® SCX-2 (Si-propylsulfonic acid) (537 g, 222 mmol) in DCM (1.5 L) was added (S)-3-amino-1 , 1 ,1-trifluoro-2-methylpropan-2-ol L-tartrate salt (step 1 )(65 g, 222 mmol) pre-dissolved in warm MeOH (500 ml). The silica suspension was stirred at RT for 30 min and the slurry was poured onto a large silica frit. The frit was washed with 10 % MeOH in DCM (3.5 litres) and the washings were discarded. The plug was eluted with 7M NHa/MeOH (300 ml) in DCM (2 litres) followed by 2M NH3/MeOH (300 ml) in DCM (1 litre). The combined washings were concentrated under reduced pressure to afford the title compound.

Intermediate D

3-Amino-1 ,1 ,1-trifluoro-2-methylpropan-2-ol hydrochloride

Figure imgf000055_0001

Step 1 : 1 ,1 ,1-trifluoro-2-methyl-3-nitropropan-2-ol To LiOH (0.193 g, 8.06 mmol) in a 3-neck roundbottom flask was added water (25 ml), nitromethane (3.76 ml, 81 mmol) and trifluoroacetone (7.95 ml, 89 mmol).

Cetyltrimethylammonium chloride (3.8 g, 10.88 mmol) and MgS04 (1.9 g, 16.12 mmol) were added and the resulting yellow solution stirred at 20-25 °C for 2 days. The reaction mixture was poured into diethyl ether (120 ml) and washed with water (3x 200 ml) and brine (1x 100 ml). The organic portion was dried over MgS04 and concentrated under reduced pressure to afford the title compound as a yellow liquid. 1 H NMR (CDCI3, 400 MHz): δ 4.7 (1 H d), δ 4.5 (1 H, d), δ 3.7 (1 H, broad), δ 1.6 (3H, s).

Step 2: 3-Amino-1 ,1 , 1-trifluoro-2-methylpropan-2-ol hydrochloride

Pd/C was added (1 g) to a 200 ml glass vessel. Ethanol (50 ml, dry) was added cautiously under an atmosphere of C02. 1 ,1 , 1-Trifluoro-2-methyl-3-nitropropan-2-ol (10 g, 57.8 mmol) was dissolved in ethanol (50 ml, dry) and added to the glass vessel. The reaction mixture was put under a positive pressure of hydrogen (5 bar) at room temperature and hydrogenated for 2 days. The reaction mixture was filtered through Celite® (filter material) and washed with excess ethanol. The solvent was removed under reduced pressure to yield a colourless oil. The oil was dissolved in MeOH (50 ml) and treated dropwise with HCI (1 M) in MeOH (30 ml). The solution was left to stir for 30 minutes and concentrated under reduced pressure azeotroping with MeCN to afford the title compound as a waxy white solid; 1 H NMR (DMSO-d6, 400MHz) δ 8.3 (3H, broad s), 6.9 (1 H, broad), 3.0 (2H, q), 1.4 (3H, s).

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Embodiments:

Embodiment 1. A compound of Formula I

Figure imgf000057_0001

I

wherein:

A is N or CR4a;

R is selected from CrC8-alkyl substituted by a substituent selected from CrC4 alkoxy, - N R iaR i b _c(=0)C^c4 aikyl, -C(=0)OCrC4 alkyl and -C(=0)N R aR ; C2-C8 alkenyl substituted by a substituent selected from C1-C4 alkoxy, -N R aR , -C(=0)d-C4 alkyl, -

Figure imgf000057_0002
alkyl and -C(=0)N R aR ; C2-C8 alkynyl substituted by a substituent selected from C1-C4 alkoxy, -N R aR ,
Figure imgf000057_0003
alkyl and - C(=0)N R aR ;

R a is selected from H and CrC4 alkyl optionally substituted with one or more halogen atoms;

R is selected from H , -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, d-C4 alkyl optionally substituted with one or more substituents selected from halogen atoms, OH , d-C4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;

or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents;

R2 is Ci-C4 haloalkyl;

R3 is H or C-i-Ce alkyl optionally substituted by one or more halogen atoms; R is selected from H; halogen; d-C4 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; -(C0-C4 alkyl)-C6-Ci4 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclyl; C C8 hydroxyalkyl; -(CH2)m-NR 7R18; -(C0-C4 alkyl)-C02R15 and -(C0-C4 alkyl)-C(0)NR 7R18;

R4 is H, or C-i-Ce alkyl optional substituted with one or more halogen;

R5 is -(CH2)m-NR 7R18, -(CH2)m-OR'; Ci-Ce alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C02R15; -(C0-C4 alkyl)-C6-Ci4 aryl or -3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; wherein the -(C0-C4 alkyl)-C6-Ci4 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group are each optionally substituted by one or more Z substituents; R6 is C-i-Ce alkyl optionally substituted by one or more halogen atoms; C3-C10 cycloalkyi; -Ci-C4 alkyl-C3-C8 cycloalkyi; C C8 alkoxy optionally substituted by one or more halogen atoms; OH; CN; halogen; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; wherein the cycloalkyi, cycloalkenyl, -(C0-C4 alkyl)-C6-C14 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group are each optionally substituted by one or more Z substituents; or

R6 is H, and R5 is -(CH2)m-NR 7R18, -(CH2)m-OR , C C8 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-C14 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S; or -(C0-C4 alkyl)-C02R15, wherein -(C0-C4 alkyl)-C6-Ci4 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclic group groups are each optionally substituted by one or more Z substituents; or R4 and R6 together with the carbon atoms to which they are bound form a 3 to 8 membered carbocyclic ring system; or R4 and R5 together form an oxo group (C=0) and R6 is CrC4 alkyl optionally substituted by one or more halogen atoms; CrC4 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-C14 aryl; or -(C0-C4 alkyl)-3 to 14 membered

heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or

R5 and R6 together with the carbon atom to which they are bound a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; or

R4 and R5 and R6 together with the carbon atom to which they are bound form a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents;

R is H, or C-i-Ce alkyl optional substituted with one or more halogen; m is 0, 1 , 2 or 3;

R8, R , R 3 and R 7 are each independently H, CrC8 alkyl optionally substituted by one or more halogen atoms, C3-Ci0 cycloalkyl or -(C C4 alkyl)-C3-C8 cycloalkyl;

R9, R 0, R 2, R 4, R 5, R 6 and R 8 are each independently H; C C8 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; C2-C8 alkynyl; C3-Ci0 cycloalkyl; C5-Ci0 cycloalkenyl; -C C4 alkyl-C3-C8 cycloalkyl; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or R8 and R9, R and R 2, R 3 and R 4, and R 7 and R 8 together with the nitrogen atom to which they are attached may form a 4 to 14 membered heterocyclic group optionally substituted by one or more Z substituents; Z is independently OH, aryl, O-aryl, benzyl, O-benzyl, C C6 alkyl optionally substituted by one or more OH groups or NH2 groups, C C6 alkyl optionally substituted by one or more halogen atoms, C C6 alkoxy optionally substituted by one or more OH groups or C1-C4 alkoxy, NR 8(S02)R21 , (S02)NR 9R21 , (S02)R21 , NR 8C(0)R21 , C(0)NR 9R21, NR 8C(0)NR 9R21 , NR 8C(0)OR19, NR 9R21, C(0)OR19, C(0)R19, SR 9, OR19, oxo, CN, N02, halogen or a 3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S;

R 9 and R2 are each independently H; C C8 alkyl; C3-C8 cycloalkyl; C1-C4 alkoxy-CrC4 alkyl; (C0-C4 alkyl)-aryl optionally substituted by one or more groups selected from Ci-C6 alkyl, C C6 alkoxy and halogen; (C0-C4 alkyl)- 3- to 14-membered heterocyclic group, the heterocyclic group including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, oxo, C C6 alkyl and C(0)Ci-C6 alkyl; (C0-C4 alkyl)-0-aryl optionally substituted by one or more groups selected from Ci-C6 alkyl, Ci-C6 alkoxy and halogen; and (C0-C4 alkyl)- 0-3- to 14- membered heterocyclic group, the heterocyclic group including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, C C6 alkyl or C(0)CrC6 alkyl; wherein the alkyl groups are optionally substituted by one or more halogen atoms, C C4 alkoxy, C(0)NH2, C(0)NHCrC6 alkyl or C(0)N(Ci-C6 alkyl)2; or

R 9 and R2 together with the nitrogen atom to which they attached form a 5- to 10- membered heterocyclic group, the heterocyclic group including one or more further heteroatoms selected from N, O and S, the heterocyclic group being optionally substituted by one or more substituents selected from OH; halogen; aryl; 5- to 10- membered heterocyclic group including one or more heteroatoms selected from N, O and S; S(0)2-aryl; S(0)2-Ci-C6 alkyl; Ci-C6 alkyl optionally substituted by one or more halogen atoms; C C6 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy; and C(0)Od-d alkyl, wherein the aryl and heterocyclic substituent groups are themselves optionally substituted by Ci-C6 alkyl, d-C6 haloalkyl or Ci-C6 alkoxy;

or a pharmaceutically acceptable salt thereof. Embodiment 2: The compound according to embodiment 1 , wherein R is selected from Ci-C4-alkyl substituted by a substituent selected from d-d alkoxy, -NR aR , -C(=0)d- C4 alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ; C2-C4 alkenyl substituted by a substituent selected from d-d alkoxy, -NR aR , -C(=0)d-d alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ; C2-C4 alkynyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)d-C4 alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ;

R a is selected from H and Ci-C alkyl optionally substituted with one or more halogen atoms;

R is selected from H, -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, d-d alkyl optionally substituted with one or more substituents selected from halogen atoms, OH, d-d-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;

or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents.

Embodiment 3: The compound according to embodiment 1 or 2, wherein R is selected from methyl or ethyl substituted by a substituent selected from d-d alkoxy, -NR aR , - C(=0)d-d alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ; ethenyl substituted by a substituent selected from d-d alkoxy, -NR aR , -C(=0)d-d alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ; and propynyl substituted by a substituent selected from d-d alkoxy, -NR aR , -C(=0)d-d alkyl, -C(=0)Od-d alkyl and -C(=0)NR aR ; R a is selected from H and d-d alkyl optionally substituted with one or more halogen atoms;

R is selected from H, -(C0-C4 alkyl)-phenyl, -(d-d alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-d alkyl)-isoxazolyl, -(C0- alkyl)-imidazolyl, -(d-d alkyl)-oxazolyl, d-d alkyl optionally substituted with one or more substituents selected from halogen atoms, OH, C"i-C4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;

or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents.

Embodiment 4: The compound according to any one of embodiments 1 to 3, wherein R is selected from methyl or ethyl substituted by a substituent selected from C C4 alkoxy, - NR aR , -C(=0)Ci-C4 alkyl, -C(=0)OCi-C4 alkyl and -C(=0)NR aR ; ethenyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OC C4 alkyl and -C(=0)NR aR ; propynyl substituted by a substituent selected from Ci-C4 alkoxy, -NR aR , -C(=0)d-C4 alkyl, -C(=0)OCi-C4 alkyl and -C(=0)NR aR ; R a is selected from H and Ci-C4 alkyl optionally substituted with one or more halogen atoms;

R is selected from H, Ci-C4 alkyl optionally substituted with one or more substituents selected from halogen atoms, OH and CrC4-alkoxy; or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents.

Embodiment 5: The compound according to any one of embodiments 1 to 4, wherein A is N. Embodiment 6: The compound according to any one of embodiments 1 to 4, wherein A is CR4a.

Embodiment 7: The compound according to any one of embodiments 1 to 6, wherein R2 is CF3CF2-, (CF3)2CH-, CH3-CF2-, CF3CF2-, CF3, CF2H-, CH3-CCI2-, CF3CFCCIH-, CBr3, CBr2H-CF3CF2CHCF3 or CF3CF2CF2CF2-, particularly R2 is CF3.

Embodiment 8: The compound according to any one of embodiments 1 to 7, wherein R3 is H or methyl. Embodiment 9: The compound according to any one of embodiments 1 to 8, wherein A is CR4a and R4a is methyl, ethyl, isopropyl and trifluoromethyl. Embodiment 10: The compound according to any one of embodiments 1 to 8, wherein A is CR4a and R4a is H.

Embodiment 1 1 : The compound according to any one of embodiments 1 to 10, wherein R4 is H or C"i-C4 alkyl optionally substituted by one or more halogen atoms.

Embodiment 12: The compound according to any one of embodiments 1 to 1 1 , wherein R5 provides a heteroatom two carbons from the amide nitrogen, wherein the heteroatom is oxygen or nitrogen. Embodiment 13: The compound according to any one of embodiments 1 to 12, wherein R4 is H, C"i-C4 alkyl optionally substituted by one or more halogen atoms or not present; R5 is C"i-C4 alkoxy optionally substituted by one or more halogen atoms; -(CH2)m- NR 7R18; -(CH2)m-OR' ,or OH;

m is 0, or 1 ;

R6 is C"i-C4 alkyl optionally substituted by one or more halogen atoms; CrC4 alkoxy optionally substituted by one or more halogen atoms; OH; CN; halogen; -(C0-C4 alkyl)- C6-C14 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or

R4 and R5 together form an oxo group (C=0); or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents;

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms. Embodiment 14: The compound according to any one of embodiments 1 to 13, wherein A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4 is H or Me;

R4a is H ;

R5 is -(CH2)m-N R 7R18; -(CH2)m-OR'; or OH ;

m is 0, or 1 ;

R6 is C C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N , O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H ; or CrC4 alkyl optionally substituted by one or more halogen atoms.

Embodiment 15: The compound according to any one of embodiment 1 to 14, wherein A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4a is H ;

R4 and R5 together form an oxo group (C=0); and

R6 is C C4 alkyl optionally substituted by one or more halogen atoms; C C4 alkoxy optionally substituted by one or more halogen atoms; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0- C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents.

Embodiment 16: The compound according to any one of embodiments 1 to 15, wherein A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H ;

R4 is H or Me; R4a is H;

R5 is -(CH2)m-NR 7R18; -(CH2)m-OR'; or OH;

m is 0, or 1 ;

R6 is C1-C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.

Embodiment 17: The compound according to any one of embodiments 1 to 16, wherein A is CR4a;

R2 is C1-C4 haloalkyl;

R3 is H;

R4 is H or Me;

R4a is H;

R5 is -(CH2)m-NR 7R18; -(CH2)m-OR; or OH;

m is 0, or 1 ;

R6 is C1-C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R17 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.

Embodiment 18: The compound according to any one of embodiments 1 to 17, wherein A is CR4a;

R2 is C C4 haloalkyl;

R3 is H;

R4 is H or Me;

R4a is H; R5 is -NR 7R18; or OH;

R6 is C C4 alkyl optionally substituted by one or more halogen atoms; or

R5 and R6 together with the carbon atoms to which they are bound form a 5 to 6 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; and

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms. Embodiment 19: The compound according to any one of embodiments 1 to 18, wherein A is CR4a;

R is C"i-C4 alkyl optionally substituted by one or more halogen atoms;

R2 is C1-C4 haloalkyl;

R3 is H;

R4 is H or Me;

R4a is H;

R5 is -NR 7R18; or OH;

R6 is C-i-C4 alkyl optionally substituted by one or more halogen atoms; and

R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.

Embodiment 20: The compound according to any one of any one of embodiments 1 to

19, wherein

Z is independently OH, d-C4 alkyl optionally substituted by one or more OH groups or NH2 groups, CrC4 alkyl optionally substituted by one or more halogen atoms, CrC4 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy, NR 9R21 , C(0)OR19, C(0)R19, SR 9, OR19, CN, N02, or halogen;

R 9 and R2 are each independently H; C C4 alkyl; C3-C6 cycloalkyl; or d-C4 alkoxy-Cr C4 alkyl, wherein all alkyls are optionally substituted with halogens.

Embodiment 21 : The compound according to any one of any one of embodiments 1 to

20, wherein Z is independently OH, CrC4 alkyl optionally substituted by one or more OH groups or NH2 groups, CrC4 alkyl optionally substituted by one or more halogen atoms, CrC4 alkoxy optionally substituted by one or more OH groups or C C4 alkoxy, C(0)OR19, C(0)R19, OR19, CN, or halogen;

R 9 is H; d-C4 alkyl; C3-C6 cycloalkyl; or d-C4 alkoxy-C-i-C4 alkyl, wherein all alkyl are optionally substituted with halogens.

Embodiment 22: The compound according to any one of any one of embodiments 1 to 21 , wherein Z is independently, d-C4 alkyl optionally substituted by one or more halogen atoms, CrC4 alkoxy or halogen.

Embodiment 23: The compound according to any one of embodiments 1 to 21 , wherein the compound is a substantially pure enantiomers with the R configuration. Embodiment 24: The compound according to any one of embodiments 1 to 21 , wherein the compound is a substantially pure enantiomers with the S configuration.

Embodiment 25: The compound according to any one of embodiments 1 to 24, wherein the compounds of Formula I include compounds of Formula II:

Figure imgf000067_0001

Figure imgf000068_0001



Figure imgf000069_0001

Embodiment 27: The compound according to embodiment 25 or 26, wherein

Figure imgf000070_0001

Figure imgf000070_0002

Embodiment 29: The compound according to any one of embodiments 25 to 27, wherein A is CR4a;

R3 is H;

R4a is H;

Figure imgf000071_0001

Embodiment 30: The compound according to any one of embodiments 25 to 27, wherein

Figure imgf000071_0002

Embodiment 31 : The compound according to any one of embodiments 25 to 27, wherein

Figure imgf000072_0001

Embodiment 32: The compound according to any one of embodiments 25 to 28, wherein A is CR4a;

R3 is H;

4a is H;

Figure imgf000072_0002

Embodiment 33: The compound according to embodiment 1 , or pharmaceutically acceptable salts thereof, selected from:

(S)-3-Amino-6-(3-(dimethylamino)propyl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5- (trifluoromethyl)picolinamide. Embodiment 34: A compound according to any one of embodiments 1 to 33 for use as a pharmaceutical.

Embodiment 35: A compound according to any one of embodiments 1 to 33 for use in the treatment of an inflammatory or obstructive airways disease or mucosal hydration.

Embodiment 36: Use of a compound according to any one of embodiments 1 to 33 in the manufacture of a medicament for use in the treatment of an inflammatory or obstructive airways disease or mucosal hydration.

Embodiment 37: A pharmaceutical composition, comprising:

the compound according to any one of embodiments 1 to 33 and

one or more pharmaceutically acceptable excipients.

Embodiment 38: A pharmaceutical combination, comprising:

a first active comprising the compound according to any one of embodiments 1 to 33, and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition.

Embodiment 39: A method for the prevention or treatment of a CFTR mediated condition or disease, comprising:

administering an effective amount of at least one compound according to any one of embodiments 1 to 33 to a subject in need of such treatment.

Claims

Claims
1. A compound of Formula I
Figure imgf000074_0001
I
wherein:
A is N or CR4a;
R is selected from d-Ce-alkyl substituted by a substituent selected from CrC4 alkoxy, - NR aR , -C(=0)Ci-C4 alkyl, -C(=0)OCi-C4 alkyl and -C(=0)NR aR ; C2-C8 alkenyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -
Figure imgf000074_0002
; C2-C8 alkynyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OC C4 alkyl and - C(=0)NR aR ;
R a is selected from H and Ci-C4 alkyl optionally substituted with one or more halogen atoms;
R is selected from H, -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, d-C4 alkyl optionally substituted with one or more substituents selected from halogen atoms, OH, CrC4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents;
or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents;
R2 is C C4 haloalkyl; R3 is H or C-i-Ce alkyl optionally substituted by one or more halogen atoms;
R is H; C C8 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; C2-C8 alkynyl; C3-Ci0 cycloalkyl; C5-Ci0 cycloalkenyl; -C1-C4 alkyl-C3-C8 cycloalkyl; Ci-C8 alkoxy optionally substituted by one or more halogen atoms; C C4 alkoxy C C4 alkyl; Ci-Ce hydroxyalkyl; OH; CN; fluorine; -(CH2)m-NR 7R18; ; -(C0-C4 alkyl)-C6-C14 aryl; -(C0- C4 alkyl)-3 to 14 membered heterocyclyl, wherein the heterocyclyl contains at least one heteroatom selected from N, O and S; or -(C0-C4 alkyl)-C02R15, wherein the cycloalkyl, cycloalkenyl, -(C0-C4 alkyl)-C6-Ci4 aryl and -(C0-C4 alkyl)-3 to 14 membered heterocyclyl groups are each optionally substituted by one or more Z substituents;
R4a is selected from H; halogen; C C4 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; -(C0-C4 alkyl)-C6-Ci4 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclyl; d-C8 hydroxyalkyl; -(CH2)m-NR 7R18; -(C0-C4 alkyl)-C02R15 and -(C0-C4 alkyl)-C(0)NR 7R18;
R5 is C C8 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; C2- C8 alkynyl; C3-Ci0 cycloalkyl; C5-Ci0 cycloalkenyl; -C1-C4 alkyl-C3-C8 cycloalkyl; Ci-C8 alkoxy optionally substituted by one or more halogen atoms; fluorine; -(CH2)m-NR 7R18; - (CH2)m-OR4; -(C0-C4 alkyl)-C6-Ci4 aryl; -(C0-C4 alkyl)-3 to 14 membered heterocyclyl, wherein the heterocyclyl contains at least one heteroatom selected from N, O and S; or - (C0-C4 alkyl)-C02R15, wherein the cycloalkyl, cycloalkenyl, -(C0-C4 alkyl)-C6-Ci4 aryl and - (C0-C4 alkyl)-3 to 14 membered heterocyclyl groups are each optionally substituted by one or more Z substituents; or
R3 and R4 together form an oxo group (C=0); or
R3 and R5 together with the carbon atoms to which they are bound form a 3 to 8 membered cycloalkyl; or
R4 and R5 together with the carbon atoms to which they are bound form a 5 to 8 membered cycloalkyl or a 5 to 8 membered heterocyclyl containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents; m is 0, 1, 2 or 3;
R8, R , R 3 and R 7 are each independently H, CrC8 alkyl optionally substituted by one or more halogen atoms, C3-Ci0 cycloalkyi or -(C1-C4 alkyl)-C3-C8 cycloalkyi;
R9, R 0, R 2, R 4, R 5, R 6 and R 8 are each independently H; C C8 alkyl optionally substituted by one or more halogen atoms; C2-C8 alkenyl; C2-C8 alkynyl; C3-Ci0 cycloalkyi; C5-Ci0 cycloalkenyl; -Ci-C4 alkyl-C3-C8 cycloalkyi; -(C0-C4 alkyl)-C6-Ci4 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclyl, wherein the heterocyclyl contains at least one heteroatom selected from N, O and S, wherein the cycloalkyi, cycloalkenyl, aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or
R8 and R9, R and R 2, R 3 and R 4, and R 7 and R 8 together with the nitrogen atom to which they are attached may form a 4 to 14 membered heterocyclyl optionally substituted by one or more Z substituents; Z is independently OH, aryl, O-aryl, benzyl, O-benzyl, C C6 alkyl optionally substituted by one or more OH groups or NH2 groups, Ci-C6 alkyl optionally substituted by one or more halogen atoms, C C6 alkoxy optionally substituted by one or more OH groups or C1-C4 alkoxy, NR30(SO2)R32, (S02)NR3 R32, (S02)R32, NR30C(O)R32, C(0)NR3 R32, NR30C(O)NR3 R32, NR30C(O)OR19, NR3 R32, C(0)OR31, C(0)R31, SR3 , OR31, oxo, CN, N02, halogen or a 3 to 14 membered heterocyclyl, wherein the heterocyclyl contains at least one heteroatom selected from N, O and S;
R30 is H or Ci-C6 alkyl; R3 and R32 are each independently H; C C8 alkyl; C3-C8 cycloalkyi; C C4 alkoxy-C C4 alkyl; (C0-C4 alkyl)-aryl optionally substituted by one or more groups selected from Ci-C6 alkyl, C C6 alkoxy and halogen; (C0-C4 alkyl)- 3- to 14-membered heterocyclyl, the heterocyclyl including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, oxo, C C6 alkyl and C(0)C C6 alkyl; (C0-C4 alkyl)-0-aryl optionally substituted by one or more groups selected from C C6 alkyl, C C6 alkoxy and halogen; and (C0-C4 alkyl)- 0-3- to 14-membered heterocyclyl, the heterocyclyl including one or more heteroatoms selected from N, O and S, optionally substituted by one or more groups selected from halogen, C C6 alkyl or C(0)C"|-C6 alkyl; wherein the alkyl groups are optionally substituted by one or more halogen atoms, C C4 alkoxy, C(0)NH2, C(0)NHC C6 alkyl or C(0)N(C C6 alkyl)2; or
R3 and R32 together with the nitrogen atom to which they attached form a 5- to 10- membered heterocyclyl, the heterocyclyl including one or more further heteroatoms selected from N, O and S, the heterocyclyl being optionally substituted by one or more substituents selected from OH; halogen; aryl; 5- to 10-membered heterocyclyl including one or more heteroatoms selected from N, O and S; S(0)2-aryl; S(0)2-Ci-C6 alkyl; Ci-C6 alkyl optionally substituted by one or more halogen atoms; C C6 alkoxy optionally substituted by one or more OH groups or d-C4 alkoxy; and C(0)OCrC6 alkyl, wherein the aryl and heterocyclic substituent groups are themselves optionally substituted by Cr C6 alkyl, Ci-C6 haloalkyl or Ci-C6 alkoxy;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein R is selected from d-C4-alkyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -
Figure imgf000077_0001
; C2-C4 alkenyl substituted by a substituent selected from C C4 alkoxy, -NR aR , -C(=0)C C4 alkyl, -C(=0)OCrC4 alkyl and - C(=0)NR aR ; C2-C4 alkynyl substituted by a substituent selected from C C4 alkoxy, - NR aR , -C(=0)Ci-C4 alkyl, -C(=0)OC C4 alkyl and -C(=0)NR aR ;
R a is selected from H and CrC4 alkyl optionally substituted with one or more halogen atoms;
R is selected from H, -(C0-C4 alkyl)-phenyl, -(C0-C4 alkyl)-pyridyl, -(C0-C4 alkyl)- pyrazolyl, -(C0-C4 alkyl)-isoxazolyl, -(C0-C4 alkyl)-imidazolyl, -(C0-C4 alkyl)-oxazolyl, C C4 alkyl optionally substituted with one or more substituents selected from halogen atoms, OH, d-C4-alkoxy; wherein the phenyl, pyridyl, pyrazolyl, isoxazolyl, imidazolyl and oxazolyl are each optionally substituted by one or more Z substituents; or R a and R together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated heterocyclyl group optionally substituted by one or more Z substituents.
3. The compound according to claim 1 or 2, wherein
A is N.
4. The compound according to claim 1 or 2, wherein A is CR4a.
5. The compound according to any one of claims 1 to 4, wherein
R2 is CF3CF2-, (CF3)2CH-, CH3-CF2-, CF3CF2-, CF3, CF2H-, CH3-CCI2-, CF3CFCCIH-, CBr3, CBrzH-CFaCFzCHCFa or CF3CF2CF2CF2-, particularly R2 is CF3.
6. The compound according to any one of claimsl to 5, wherein R3 is H or methyl.
7. The compound according to any one of claims 1 to 6, wherein A is CR4a and R4a is methyl, ethyl, isopropyl and trifluoromethyl.
8. The compound according to any one of claims 1 to 6, wherein A is CR4a and R4a is H.
9. The compound according to any one of claims 1 to 8, wherein R4 is H or CrC4 alkyl optionally substituted by one or more halogen atoms.
10. The compound according to any one of claims 1 to 9, wherein R4 is H, d-C4 alkyl optionally substituted by one or more halogen atoms or not present;
R5 is C"i-C4 alkoxy optionally substituted by one or more halogen atoms; -(CH2)m- NR 7R18; -(CH2)m-OR' ,or OH;
m is 0, or 1 ;
R6 is C"i-C4 alkyl optionally substituted by one or more halogen atoms; CrC4 alkoxy optionally substituted by one or more halogen atoms; OH; CN; halogen; -(C0-C4 alkyl)- C6-C14 aryl; or -(C0-C4 alkyl)-3 to 14 membered heterocyclic group, wherein the heterocyclic group contains at least one heteroatom selected from N, O and S, wherein the aryl and heterocyclyl groups are each optionally substituted by one or more Z substituents; or
R4 and R5 together form an oxo group (C=0); or
R5 and R6 together with the carbon atoms to which they are bound form a 5 to 8 membered heterocyclic ring system containing one or more heteroatoms selected from N, O and S, wherein the ring system is optionally substituted by one or more Z substituents;
R 7 and R 8 are each independently H; or C C4 alkyl optionally substituted by one or more halogen atoms.
1 1. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, selected from:
(S)-3-Amino-6-(3-(dimethylamino)propyl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5- (trifluoromethyl)picolinamide.
12. A compound according to any one of embodiments 1 to 1 1 for use as a
pharmaceutical.
13. A compound according to any one of embodiments 1 to 1 1 for use in the treatment of an inflammatory or obstructive airways disease or mucosal hydration.
14. Use of a compound according to any one of embodiments 1 to 11 in the manufacture of a medicament for use in the treatment of an inflammatory or obstructive airways disease or mucosal hydration.
15. A pharmaceutical composition, comprising:
the compound according to any one of claims 1 to 1 1 and
one or more pharmaceutically acceptable excipients.
16. A pharmaceutical combination, comprising:
a first active comprising the compound according to any one of claims 1 to 11 , and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition.
17. A method for the prevention or treatment of a CFTR mediated condition or disease, comprising:
administering an effective amount of at least one compound according to any one of claims 1 to 1 1 to a subject in need of such treatment.
PCT/IB2012/054820 2011-09-16 2012-09-14 Pyridine/pyrazine amide derivatives WO2013038381A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161535707P true 2011-09-16 2011-09-16
US61/535,707 2011-09-16

Publications (1)

Publication Number Publication Date
WO2013038381A1 true WO2013038381A1 (en) 2013-03-21

Family

ID=47116136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054820 WO2013038381A1 (en) 2011-09-16 2012-09-14 Pyridine/pyrazine amide derivatives

Country Status (1)

Country Link
WO (1) WO2013038381A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906900B2 (en) 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
WO2016200851A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
WO2017009804A1 (en) 2015-07-16 2017-01-19 Abbvie S.Á.R.L. Substituted tricyclics and method of use
WO2017060879A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
WO2017060873A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
WO2017060874A1 (en) 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017187321A1 (en) 2016-04-26 2017-11-02 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
WO2017208115A1 (en) 2016-06-03 2017-12-07 AbbVie S.à.r.l. Heteroaryl substituted pyridines and methods of use
WO2018065921A1 (en) 2016-10-07 2018-04-12 Abbvie S.Á.R.L. Substituted pyrrolidines as cftr modulators
WO2018065962A1 (en) 2016-10-07 2018-04-12 AbbVie S.à.r.l. Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
WO2018154519A1 (en) 2017-02-24 2018-08-30 AbbVie S.à.r.l. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2019053634A1 (en) 2017-09-14 2019-03-21 AbbVie S.à.r.l. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Citations (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714357A (en) 1968-07-15 1973-01-30 Rech D Applic Scient Sogeras S Pharmaceutical compositions comprising quinuclidinol derivatives
EP0424021A1 (en) 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators
WO1992019594A1 (en) 1991-05-02 1992-11-12 Smithkline Beecham Corporation Pyrrolidinones
JPH0525045B2 (en) 1985-08-09 1993-04-09 Noritoshi Nakabachi
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
WO1993019749A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
WO1998018796A1 (en) 1996-10-28 1998-05-07 Novartis Ag Naphthyridine derivatives
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
WO1999064035A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2000000531A1 (en) 1998-06-30 2000-01-06 The Dow Chemical Company Polymer polyols and a process for the production thereof
WO2000066559A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
WO2000066558A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
WO2000075114A1 (en) 1999-06-04 2000-12-14 Novartis Ag Beta2-adrenoceptor agonists
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
WO2001004118A2 (en) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
WO2001013953A2 (en) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
WO2001042193A1 (en) 1999-12-08 2001-06-14 Theravance, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2001083462A1 (en) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
WO2002000652A1 (en) 2000-06-27 2002-01-03 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
WO2002000679A2 (en) 2000-06-28 2002-01-03 Novartis Ag 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
WO2002010143A1 (en) 2000-07-28 2002-02-07 Schering Aktiengesellschaft Non-steroidal inflammation inhibitors
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US20020055651A1 (en) 1999-06-02 2002-05-09 Moran Edmund J. Beta2-adrenergic receptor agonists
WO2002042298A1 (en) 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
WO2002053564A2 (en) 2000-12-28 2002-07-11 Almirall Prodesfarma Ag Quinuclidine derivatives and their use as m3 antagonists
WO2002066422A1 (en) 2001-02-14 2002-08-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
WO2002100879A1 (en) 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
WO2003000840A2 (en) 2001-06-21 2003-01-03 Diversa Corporation Nitrilases
WO2003024439A1 (en) 2001-09-14 2003-03-27 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003033495A1 (en) 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2003035668A2 (en) 2001-10-20 2003-05-01 Glaxo Group Limited Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
WO2003039544A1 (en) 2001-11-05 2003-05-15 Novartis Ag Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2003042164A1 (en) 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
WO2003064445A1 (en) 2002-01-31 2003-08-07 Glaxo Group Limited 17-alpha-heterocyclic esters of androstane derivatives having anti-inflammatory activity
WO2003072539A1 (en) 2002-02-28 2003-09-04 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003087094A2 (en) 2002-04-16 2003-10-23 Almirall Prodesfarma Ag Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003091204A1 (en) 2002-04-25 2003-11-06 Glaxo Group Limited Phenethanolamine derivatives
WO2003099807A1 (en) 2002-05-29 2003-12-04 Almirall Prodesfarma S.A. New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
WO2003099764A1 (en) 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
WO2003101932A2 (en) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003104205A1 (en) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloximes
WO2003104204A1 (en) 2002-06-05 2003-12-18 Merck Patent Gmbh Pyridazine derivatives
WO2003104195A1 (en) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
WO2004000814A1 (en) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. 8-(biaryl) quinoline pde4 inhibitors
WO2004000839A1 (en) 2002-06-19 2003-12-31 Merck Patent Gmbh Thiazole derivatives as phosphodiesterase iv inhibitors
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004005285A1 (en) 2002-07-02 2004-01-15 Almirall Prodesfarma Ag New quinuclidine amide derivatives
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004016578A2 (en) 2002-07-25 2004-02-26 Glaxo Group Limited Arylethanolamine beta2-adrenoreceptor agonist compounds
WO2004016601A1 (en) 2002-08-09 2004-02-26 Novartis Ag Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
WO2004018422A1 (en) 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2004018451A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004018465A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004018457A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2004018431A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018425A1 (en) 2002-08-21 2004-03-04 Astrazeneca Ab N-4-piperidinyl compounds as ccr5 modulators
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
WO2004019945A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
WO2004019935A1 (en) 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
WO2004022547A1 (en) 2002-09-06 2004-03-18 Glaxo Group Limited Phenethanolamine derivatives and their use in the treatment of respiratory diseases
WO2004026841A1 (en) 2002-09-18 2004-04-01 Sumitomo Pharmaceuticals Co., Ltd. Novel 6-substituted uracil derivative and therapeutic agent for allergic disease
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2004026873A1 (en) 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2004107299A (en) 2002-09-20 2004-04-08 Japan Energy Corp New 1-substituted urasil derivative and therapeutic agent for allergic disease
WO2004032921A1 (en) 2002-10-11 2004-04-22 Pfizer Limited Indole derivatives as beta-2 agonists
WO2004033412A1 (en) 2002-10-04 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments
WO2004037773A1 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
WO2004037768A2 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivatives
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
WO2004037805A1 (en) 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004039762A1 (en) 2002-11-01 2004-05-13 Glaxo Group Limited Phenethanolamine derivatives for the treatment of respiratory diseases
WO2004039766A1 (en) 2002-11-01 2004-05-13 Glaxo Group Limited Phenylethanolamine derivatives for the treatment of respiratory diseases
WO2004039827A2 (en) 2002-10-30 2004-05-13 Glaxo Group Limited Glucocorticosteroids having a specific 17a-sidechain useful as antiinflammatory agents
WO2004045618A2 (en) 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicaments for the treatment of chronic obstructive pulmonary diseases
WO2004045607A1 (en) 2002-11-15 2004-06-03 Elbion Ag Novel hydroxyindoles, use as inhibitors of phosphodiesterase 4 and method for production thereof
WO2004046083A1 (en) 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
DE10261874A1 (en) 2002-12-20 2004-07-08 Schering Ag NSAIDs
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004066920A2 (en) 2003-01-21 2004-08-12 Merck & Co. Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
US20040167167A1 (en) 2003-02-14 2004-08-26 Mathai Mammen Biphenyl derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004080964A1 (en) 2003-03-14 2004-09-23 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004108676A1 (en) 2003-06-04 2004-12-16 Pfizer Limited 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists
WO2004108765A2 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular aspergillus polypeptides
WO2008141119A2 (en) * 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
US20080286204A1 (en) * 2007-05-09 2008-11-20 Hadida-Ruah Sara S Modulators of cftr
WO2009150137A2 (en) * 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2011113894A1 (en) 2010-03-19 2011-09-22 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf

Patent Citations (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714357A (en) 1968-07-15 1973-01-30 Rech D Applic Scient Sogeras S Pharmaceutical compositions comprising quinuclidinol derivatives
JPH0525045B2 (en) 1985-08-09 1993-04-09 Noritoshi Nakabachi
EP0424021A1 (en) 1989-10-19 1991-04-24 Pfizer Limited Antimuscarinic bronchodilators
US5171744A (en) 1989-10-19 1992-12-15 Pfizer Inc. Antimuscarinic bronchodilators
WO1992019594A1 (en) 1991-05-02 1992-11-12 Smithkline Beecham Corporation Pyrrolidinones
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
WO1993019749A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
WO1998018796A1 (en) 1996-10-28 1998-05-07 Novartis Ag Naphthyridine derivatives
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
WO1999064035A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2000000531A1 (en) 1998-06-30 2000-01-06 The Dow Chemical Company Polymer polyols and a process for the production thereof
WO2000066558A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
WO2000066559A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US20020055651A1 (en) 1999-06-02 2002-05-09 Moran Edmund J. Beta2-adrenergic receptor agonists
WO2000075114A1 (en) 1999-06-04 2000-12-14 Novartis Ag Beta2-adrenoceptor agonists
WO2001004118A2 (en) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
WO2001013953A2 (en) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
WO2001042193A1 (en) 1999-12-08 2001-06-14 Theravance, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2001083462A1 (en) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
WO2002000652A1 (en) 2000-06-27 2002-01-03 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
WO2002000679A2 (en) 2000-06-28 2002-01-03 Novartis Ag 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
WO2002010143A1 (en) 2000-07-28 2002-02-07 Schering Aktiengesellschaft Non-steroidal inflammation inhibitors
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
WO2002042298A1 (en) 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
WO2002051841A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
WO2002053564A2 (en) 2000-12-28 2002-07-11 Almirall Prodesfarma Ag Quinuclidine derivatives and their use as m3 antagonists
WO2002066422A1 (en) 2001-02-14 2002-08-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
WO2002100879A1 (en) 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
WO2003000840A2 (en) 2001-06-21 2003-01-03 Diversa Corporation Nitrilases
WO2003024439A1 (en) 2001-09-14 2003-03-27 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003033495A1 (en) 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2003035668A2 (en) 2001-10-20 2003-05-01 Glaxo Group Limited Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
WO2003039544A1 (en) 2001-11-05 2003-05-15 Novartis Ag Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2003042164A1 (en) 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
WO2003064445A1 (en) 2002-01-31 2003-08-07 Glaxo Group Limited 17-alpha-heterocyclic esters of androstane derivatives having anti-inflammatory activity
WO2003072539A1 (en) 2002-02-28 2003-09-04 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003087094A2 (en) 2002-04-16 2003-10-23 Almirall Prodesfarma Ag Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
WO2003091204A1 (en) 2002-04-25 2003-11-06 Glaxo Group Limited Phenethanolamine derivatives
WO2003099764A1 (en) 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
WO2003099807A1 (en) 2002-05-29 2003-12-04 Almirall Prodesfarma S.A. New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
WO2003101932A2 (en) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003104204A1 (en) 2002-06-05 2003-12-18 Merck Patent Gmbh Pyridazine derivatives
WO2003104195A1 (en) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
WO2003104205A1 (en) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloximes
WO2004000839A1 (en) 2002-06-19 2003-12-31 Merck Patent Gmbh Thiazole derivatives as phosphodiesterase iv inhibitors
WO2004000814A1 (en) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. 8-(biaryl) quinoline pde4 inhibitors
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004005285A1 (en) 2002-07-02 2004-01-15 Almirall Prodesfarma Ag New quinuclidine amide derivatives
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004016578A2 (en) 2002-07-25 2004-02-26 Glaxo Group Limited Arylethanolamine beta2-adrenoreceptor agonist compounds
WO2004016601A1 (en) 2002-08-09 2004-02-26 Novartis Ag Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
WO2004018457A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2004018451A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004018431A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
WO2004018465A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004018425A1 (en) 2002-08-21 2004-03-04 Astrazeneca Ab N-4-piperidinyl compounds as ccr5 modulators
WO2004018422A1 (en) 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
WO2004019945A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
WO2004019935A1 (en) 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
WO2004022547A1 (en) 2002-09-06 2004-03-18 Glaxo Group Limited Phenethanolamine derivatives and their use in the treatment of respiratory diseases
WO2004026841A1 (en) 2002-09-18 2004-04-01 Sumitomo Pharmaceuticals Co., Ltd. Novel 6-substituted uracil derivative and therapeutic agent for allergic disease
WO2004026873A1 (en) 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2004107299A (en) 2002-09-20 2004-04-08 Japan Energy Corp New 1-substituted urasil derivative and therapeutic agent for allergic disease
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2004033412A1 (en) 2002-10-04 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel beta mimetics with extended duration of action, method for production and use thereof as medicaments
WO2004032921A1 (en) 2002-10-11 2004-04-22 Pfizer Limited Indole derivatives as beta-2 agonists
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
WO2004037805A1 (en) 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004037768A2 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivatives
WO2004037773A1 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
WO2004039827A2 (en) 2002-10-30 2004-05-13 Glaxo Group Limited Glucocorticosteroids having a specific 17a-sidechain useful as antiinflammatory agents
WO2004039766A1 (en) 2002-11-01 2004-05-13 Glaxo Group Limited Phenylethanolamine derivatives for the treatment of respiratory diseases
WO2004039762A1 (en) 2002-11-01 2004-05-13 Glaxo Group Limited Phenethanolamine derivatives for the treatment of respiratory diseases
WO2004046083A1 (en) 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
WO2004045618A2 (en) 2002-11-15 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicaments for the treatment of chronic obstructive pulmonary diseases
WO2004045607A1 (en) 2002-11-15 2004-06-03 Elbion Ag Novel hydroxyindoles, use as inhibitors of phosphodiesterase 4 and method for production thereof
DE10261874A1 (en) 2002-12-20 2004-07-08 Schering Ag NSAIDs
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004066920A2 (en) 2003-01-21 2004-08-12 Merck & Co. Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
WO2004074812A2 (en) 2003-02-14 2004-09-02 Theravance Inc Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004074246A2 (en) 2003-02-14 2004-09-02 Theravance Inc. Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20040167167A1 (en) 2003-02-14 2004-08-26 Mathai Mammen Biphenyl derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004080964A1 (en) 2003-03-14 2004-09-23 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004108676A1 (en) 2003-06-04 2004-12-16 Pfizer Limited 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists
WO2004108765A2 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular aspergillus polypeptides
WO2008141119A2 (en) * 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
US20080286204A1 (en) * 2007-05-09 2008-11-20 Hadida-Ruah Sara S Modulators of cftr
WO2009150137A2 (en) * 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2011113894A1 (en) 2010-03-19 2011-09-22 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Functional Group Transformations", 1995, PERGAMON
"Comprehensive Organic Synthesis", 1991, PERGAMON
"Comprehensive Organic Transformations", 1989, VCH
"March's Organic Chemistry", 2001
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
BAXTER DF; KIRK M; GARCIA AF; RAIMONDI A; HOLMQVIST MH; FLINT KK; BOJANIC D; DISTEFANO PS; CURTIS R; XIE Y.: "A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels.", J BIOMOL SCREEN, vol. 7, no. 1, February 2002 (2002-02-01), pages 79 - 85
FINKEL A; WITTEL A; YANG N; HANDRAN S; HUGHES J; COSTANTIN J.: "Population patch clamp improves data consistency and success rates in the measurement of ionic currents.", J BIOMOL SCREEN., vol. 11, no. 5, August 2006 (2006-08-01), pages 488 - 96
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY AND SONS
HIRSH ET AL., J PHARM EXP THER, 2004
MOODY ET AL., AM J PHYSIOL CELL PHYSIOL, 2005
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9765068B2 (en) 2012-12-21 2017-09-19 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9266836B2 (en) 2012-12-21 2016-02-23 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365519B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9388173B2 (en) 2012-12-21 2016-07-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10307413B2 (en) 2012-12-21 2019-06-04 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US10150758B2 (en) 2012-12-21 2018-12-11 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9221794B2 (en) 2012-12-21 2015-12-29 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8906900B2 (en) 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9777008B2 (en) 2012-12-21 2017-10-03 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9675614B2 (en) 2012-12-21 2017-06-13 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9732072B2 (en) 2012-12-21 2017-08-15 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
WO2016200851A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
WO2017009804A1 (en) 2015-07-16 2017-01-19 Abbvie S.Á.R.L. Substituted tricyclics and method of use
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US9890158B2 (en) 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US9796711B2 (en) 2015-10-09 2017-10-24 Abbvie S.Á.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use
US10130622B2 (en) 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis
WO2017060873A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
US10259810B2 (en) 2015-10-09 2019-04-16 AbbVie S.à.r.l. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
WO2017060879A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
WO2017060874A1 (en) 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10118916B2 (en) 2016-04-26 2018-11-06 Abbvie S.Á.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
WO2017187321A1 (en) 2016-04-26 2017-11-02 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
WO2017208115A1 (en) 2016-06-03 2017-12-07 AbbVie S.à.r.l. Heteroaryl substituted pyridines and methods of use
WO2018065921A1 (en) 2016-10-07 2018-04-12 Abbvie S.Á.R.L. Substituted pyrrolidines as cftr modulators
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018065962A1 (en) 2016-10-07 2018-04-12 AbbVie S.à.r.l. Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
WO2018154519A1 (en) 2017-02-24 2018-08-30 AbbVie S.à.r.l. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2018154493A1 (en) 2017-02-24 2018-08-30 AbbVie S.à.r.l. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019053634A1 (en) 2017-09-14 2019-03-21 AbbVie S.à.r.l. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Similar Documents

Publication Publication Date Title
EP2231280B1 (en) Amiloride-like Pyrazine-carboxamides as ENaC blockers
CN1308310C (en) Nitrogenous aromatic ring compounds
EP2498607B1 (en) Kinase inhibitors
ES2694787T3 (en) Solid forms of a selective CDK4 / 6 inhibitor
US8318723B2 (en) Pyrazine compounds, their use and methods of preparation
US8314112B2 (en) Pyrrolopyrimidines and pyrrolopyridines
JP4208938B2 (en) Salt of proline derivative or a solvate thereof, and a manufacturing method thereof
FI112864B (en) Process for the preparation of fluoroalkoxy-substituted benzamides
US20090209539A1 (en) Pyrimidine derivatives as alk-5 Inhibitors
CN101842361B (en) Pyrazinone derivatives and their use in the treatment of lung diseases
CN102245573B (en) Heteroaryl derivatives as cftr modulators
US20080103141A1 (en) New compounds
EP3168213B1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
EP2300010B1 (en) Pyrazine derivatives as epithelial sodium channel blockers
US20110166161A1 (en) Heterocyclic carboxamide compounds
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CN102066360B (en) Quinoline or isoquinoline substituted P2X7 antagonists
CA2661333C (en) Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
CN101827844B (en) Imidazo [1,2-a] pyridine derivatives useful as ALK inhibitors
CN101861316B (en) Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2008005569A2 (en) Modulators of metabolism and the treatment of disorders related thereto
US9527835B2 (en) Cyclopropylamines as LSD1 inhibitors
JP2013508414A (en) Composition for the treatment of cystic fibrosis and other chronic diseases
CN105531268B (en) For the treatment of cystic fibrosis novel compounds and pharmaceutical compositions
HUE026220T2 (en) Pyridyl derivatives as CFTR modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12780541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12780541

Country of ref document: EP

Kind code of ref document: A1